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The goal of the work presented herein was to further our understanding of 
Bovine Leukocyte Antigen (BoLA) class I diversity of Holstein cattle and develop tools 
to measure class I restricted T cell responses to intracellular pathogens such as foot and 
mouth disease virus (FMDV) following vaccination. BoLA is a highly polymorphic gene 
region that allows the bovine immune system to differentiate pathogen-infected cells 
from healthy cells. Immune surveillance by CD8+ T cells plays an important role in 
clearing viral infections. These CD8+ T cells recognize BoLA class I molecules bearing 
epitopes (antigenic peptides) of intracellular origin in their peptide binding groove. 
Polymorphisms in the peptide binding region of class I molecules determine affinity of 
peptide binding and stability during antigen presentation. Different antigen peptide motifs 
are associated with specific genetic sequences of class I molecules. In order to better 
understand the adaptive immune response mediated by BoLA molecules, technologies 
from human medicine such as high-throughput sequencing, biochemical affinity and 
stability assays, tetramers and IFN-γ ELIspot assays could be applied. Therefore, it was 
hypothesized that we can translate these technologies from the study of human T cell 
responses to the study of cattle immunity. 
The first objective was to establish a comprehensive method for genotyping 
BoLA of Holstein cattle by using Illumina MiSeq, Sanger sequencing and polymerase 
chain reaction sequence-specific primers (PCR-SSP) (See Chapter 2). This is an 
important first step in order to study the BoLA restricted immune responses following 
FMDV vaccination. The second objective was to define the FMDV capsid protein 
peptide repertoire bound by BoLA class I molecules using bioinformatics and 
biochemical affinity and stability assays to facilitate the identification of T cell epitopes 
(See Chapter 3). The third objective was to demonstrate clonal T cell expansion for 
specific epitope polypeptides using ex-vivo multi-color flow cytometric MHC-epitope 
complexes (tetramers), followed by IFN-γ production measured by an ELIspot assay to 
quantify and define the antigen specific response of Holstein cattle to FMDV vaccination 
(see Chapter 4). In this, my dissertation studies aimed to improve our understanding of 
the BoLA class I restricted T-cell responses to candidate FMDV vaccines in Holstein 
cattle. In this manner, my research will improve animal health through the production of 
assays for characterizing the bovine immune response to intracellular pathogens and 
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1. CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
1.1. Introduction 
Cattle are one of the most economically important livestock species in the United 
States and worldwide. Cattle were first domesticated among migratory human 
populations approximately 10,000 years ago (Ensminger 1993). They are not only a 
valuable source of milk, meat, and hide, but also can be used as draft animals. In 2015, 
the global cattle population provided 63 million tonnes of meat and 126 million tonnes of 
skimmed cow milk (FAOSTAT 2013). The continual rise in the world’s population is 
estimated to reach 9 billion people by the year 2040 (Bureau 2015). This increase will 
demand a need for animal protein; cattle are import source for this protein. Infectious 
diseases such as foot and mouth disease virus (FMDV) are a major economic constraint 
on cattle productivity and a threat to food safety. Although cattle are primarily bred for 
their milk and meat production, disease resistance is a quality strongly desired by most 
producers.   
The major histocompatibility complex (MHC) genes play a seminal role in the 
immune response of mammalian species, such as cattle. MHC is a set of genes that bind 
pathogen-derived peptides and presents them on the surface of nucleated cells for 
recognition by specialized T cells. As a result of pathogen recognition via MHC 
presentation, T cells and B cells are activated, expanded and differentiated into effector 
cells, which help defend the body against pathogens. One of the key features of the MHC 
gene region is that it is highly polymorphic. This high polymorphism allows individuals 
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with diverse MHC genes bind and recognize peptides derived from numerous different 
pathogens (Sette and Sidney 1999).  
1.2. MHC Discovery 
The MHC was first described in mice in the 1940’s by George Snell and Peter 
Gorer (Gorer and Schutze 1938; Snell 1948). Initially, the MHC was known for its role in 
immune acceptance or rejection of transplant tissues. It was later discovered that immune 
surveillance by CD8+ or CD4+ T cells begins with the recognition of foreign or self-
antigens presented at the cell surface by MHC class I or II molecules (Bjorkman and 
Parham 1990; Maffei et al. 1997). The most selective event in antigen presentation is the 
binding of the peptide to the MHC molecule (Yewdell and Bennink 1999). Selection of T 
cells that are self-MHC restricted occurs in the thymus during T cell maturation 
(Goldrath and Bevan 1999). Those T cells that do not recognize self-MHC die and only 
the T cells that express antigen receptors for specific peptides bound to self MHC are 
appropriately stimulated and survive (Goldrath and Bevan 1999). CD8+ T cells are MHC 
class I restricted and CD4+ T cells are class II MHC restricted. 
1.3. MHC Molecules 
1.3.1. MHC Class I  
MHC class I molecules are a trimeric complex composed of a heavy α chain 
chain (45 kDa) noncovalently associated with a β2-microglobulin (β2M) light chain, (12 
kDa) and exogenous peptide (Bjorkman and Parham 1990; Grey et al. 1973) (Figure 1-1). 
The α chain is polymorphic and encoded by the MHC gene. It is composed of three 
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extracellular domains, α1, α2, α3, a hydrophobic transmembrane domain and hydrophilic 
cytoplasmic tail (Flutter and Gao 2004). The hypervariable α1 and α2 domains form the 
peptide binding groove of class I molecules. The other polypeptide chain that composes 
the MHC molecule is β2-microglobulin, which is encoded by the β2M gene. The α3 and 
β2M are more conserved and are homologous to immunoglobulin domains (Becker and 
Reeke 1985; Bjorkman and Parham 1990; Grey et al. 1973).  
 In cattle the MHC is called the bovine leukocyte antigen (BoLA) gene locus. 
The existence of BoLA was established over 35 years ago (Spooner et al. 1979). Similar 
to humans and mice, cattle have three MHC gene classes: class I, II and III.  BoLA class I 
and II both play a role in antigen presentation, whereas the function of BoLA class III has 
been associated with components of the complement system (Ellis and Hammond 2014; 
McShane et al. 2001). In contrast to humans, who have a fixed complement of three 
classical class I genes, human leukocyte antigen (HLA)-A, B and C, cattle express a 
variable number of genes expressed in a range of different combinations. To date, six 
BoLA class I genes have been identified. Typically 1-3 of these genes are expressed in 
variable combinations to compose a variety of haplotypes. 13 haplotype configurations 
have been identified, primarily from European cattle populations (Codner et al. 2012a). 
Understanding the evolutionary history of the MHC regions in Cetariodactyls, such as 
cattle will provide insights into predicting and manipulating the T cell responses in these 
species. Over 13 million years ago there have been several evolutionary events that have 
contributed the divergence of the Bovinae MHC subfamily (Ellis and Ballingall 1999; 
Holmes et al. 2003). These events are attributed to large-scale gene block duplications 
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and selective pressures, which contribute to the overall diversity in the BoLA class I 
genes (Ellis and Ballingall 1999). The BoLA variants have important roles in biological 
functions, such as influencing the immune response and susceptibility to infectious 
diseases (Ellis and Ballingall 1999; Ellis and Hammond 2014; Holmes et al. 2003).   
 The overall genomic organization of the MHC in cattle differs slightly from that 
in mice and humans. The BoLA region in cattle is split into three gene classes, however 
BoLA class II region is further divided into class IIa and class IIb (Sharif et al. 1998). 
The overall size of the BoLA class I gene region is approximately 400 Kb and is located 
on chromosome 23 (Di Palma et al. 2002). All validated BoLA allele sequences are 




Figure 1-1: Simplified structure of MHC class I and II molecules. Figure made by author. 
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1.3.2. Processing of Cytosolic Antigens for MHC Class I Presentation 
Pathogen-derived polypeptides between 8-12 amino acids in length are 
presented by cell surface MHC class I molecules to T cells. For example, during FMDV 
viral infection of a host cell, FMDV antigens found in the cytosol or nucleus are 
processed and presented via the endogenous pathway within nucleated cells (Maffei et al. 
1997). In the endogenous pathway, proteins present in the cytosol or nucleus are 
degraded by the proteasome into short peptides. A small polypeptide, ubiquitin, targets 
these proteins for proteasomal degradation by covalent linkage. Ubiquitinated proteins 
are unfolded and “threaded” through the proteasome. LMP-2 and LMP-7 are two 
catalytic subunits present in 1500 kD proteasomes that are encoded by MHC genes and 
are important for generating class I peptides (Yewdell et al. 1994). The ATP-dependent 
transport of the resulting peptides from the cytosol into the lumen of the endoplasmic 
reticulum (ER) is accomplished by the transporter associated with antigen processing 
(TAP) (Maffei et al. 1997). Once on the luminal side of the ER, the TAP protein is 
noncovalently attached to newly synthesized MHC class I molecules by tapasin, a linker 
protein (Peaper and Cresswell 2008). Upon antigen sensitization T cells can cause an 
upregulation of IFN-γ, which increases synthesis of LMP-2 and LMP-7. This in turn 
enhances antigen presentation, as well as TAP, thus enhancing killing of virus-infected 
cells (Yewdell et al. 1994).  
Before the translocated peptide can bind to an MHC molecule, the MHC 
molecule must first be properly assembled. ER chaperone proteins, such as calnexin and 
calreticulin, assist with the correct folding of the α chains. β2M is synthesized in the ER, 
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stabilizing the class I α chains. The peptide is trimmed to 8-12 amino acids in length by 
the ER-resident aminopeptidase (ERAP) for correct loading into MHC class I. Once the 
peptide is able to bind in the cleft of the MHC class I molecule, tapasin is released and 
the peptide-MHC complexes are subsequently trafficked through the Golgi. They are then 
glycosylated and transported in secretory vesicles, which then fuse with the cellular 
membrane (Figure 1-2). Presentation of the MHC-peptide complexes on the surface of 
the infected cells permits interaction with T cell receptors (TCRs) expressed on the 
surface of CD8+ T cells. T cell receptors demonstrate specificity to individual MHC-
peptide complexes; thus, specificity of the immune response to specific peptides is 
regulated at both the level of binding of the expressed MHC-peptide complex to 
complementary receptors of T cell populations and the binding of pathogen-derived 
polypeptide in the binding cleft of the MHC molecules.  
1.3.3. MHC Class II 
MHC class II molecules are heterodimers composed of 33 kDa α-chain and 28 
kDa β-chain associated by noncovalent interactions (Figure 1-1) (Schafer et al. 1995). 
Each chain is composed of two α or two β domains. Similar to MHC class I molecules, 
MHC class II molecules contain transmembrane and cytoplasmic domains (Figure 1-1). 
The groove between β1 and α1 domains is a highly polymorphic peptide binding groove.  
In humans, MHC class II molecules are encoded by three polymorphic genes: 
HLA-DR, HLA-DQ and HLA-DP (Neefjes et al. 2011). Cattle express only two BoLA 
class II proteins, DR and DQ (Norimine and Brown 2005). The BoLA-DQ molecules are 
duplicated and generate diversity through inter-haplotype and intra-haplotype pairing 
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(Norimine and Brown 2005). The DRα chain in humans and cattle is monomorphic. The 
only source of diversity in DR molecules is from the polymorphic DRβ chain (Norimine 
and Brown 2005). In cattle only the DRβ3 gene is functional.  
1.3.4. Processing of Endocytosed Antigens for MHC Class II Presentation 
MHC class II molecules are primarily expressed by antigen presenting cells 
(APCs), such as dendritic cells (DCs), macrophages and B cells (Neefjes et al. 2011). 
APCs endocytose and process protein antigens through the endosomal pathway, proteins 
are continuously degraded and cycled through early and late endosomes and lastly into 
lysosomes. Within these compartments the internalized proteins are exposed to 
increasingly acidic conditions and are degraded enzymatically by proteases, such as 
cathepsins, to produce peptides (Roche and Furuta 2015).  
MHC Class II molecules are synthesized in the ER. A polypeptide chaperone 
protein termed the invariant chain (Ii) binds to the peptide binding cleft of the MHC 
molecule in the ER. Ii promotes folding and assembly of class II molecules and facilitates 
MHC transfer to the endosomal pathway (Roche and Furuta 2015). Once the Ii –MHC 
class II heterotrimer is transported through the Golgi to an endosome called the MHC 
class II compartment (MIIC), cathepsin S degrades the Ii, leaving the class II-associated Ii 
peptide (CLIP) fragment in the peptide binding groove of the MHC class II dimer (Roche 
and Furuta 2015). The CLIP fragment is later exchanged for an antigenic peptide with the 
help of chaperone protein HLA-DM (Neefjes et al. 2011). The peptide-MHC complexes 
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are then transported to the cell surface, where they are displayed for recognition by CD4+ 
T helper cells (Figure 1-2). 
 
Figure 1-2: Schematic diagram of antigen presentation pathways by MHC class I and II (Heath and 
Carbone 2001). 
1.3.5. Non-classical MHC Molecules 
The MHC class I and II regions encode a number of genes termed ‘non-
classical’ (Birch et al. 2008). Non-classical MHC molecules are non-polymorphic, 
encode heavy chains with truncated cytoplasmic domains and are not ubiquitously 
expressed (Birch et al. 2008). In humans, HLA-E, -F and -G constitute the non-classical 
class I genes. Non-classical molecules in humans and mice have been shown to play a 
role in immune evasion, natural killer (NK) cell activation and reproduction (Hofstetter et 
al. 2011).  In cattle there are five non-classical genes (NC1-5), composed of 19 alleles in 
IPD-MHC. Previous transcription studies found that NC1 is ubiquitously expressed and 
NC2-5 expression is much more variable (Codner et al. 2012a; Ellis and Hammond 
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2014). NC1 is found adjacent to the classical class I genes on chromosome 23, whereas 
NC2-4 are located 500 Kb centromeric to the cluster of classical class I genes, NC5 has 
not been mapped (Birch et al. 2008). The functional importance of these non-classical 
MHC class I genes in bovine is not well understood.  
1.4. Polymorphism & Generation of MHC Diversity 
1.4.1. Genetic Mechanisms Contributing to MHC Diversity  
The MHC contains the most polymorphic genes described in vertebrates 
(Piertney and Oliver 2006). As of July 2015, there were 3,192 HLA-A, 3,977 HLA-B and 
2,740 HLA-C known alleles (http://hla.alleles.org/nomenclature/stats.html).  In cattle 
there are presently 114 BoLA class I alleles including 95 classical alleles and 19 non-
classical alleles in IPD-MHC. In humans and cattle, MHC polymorphisms arise from 
point mutations, gene duplication or deletion and intra-locus recombination (Codner et al. 
2012a; Codner et al. 2012b; Ellis and Hammond 2014; Parham et al. 1995). The majority 
of the MHC variation lies within the peptide binding region of class I and II molecules 
(Parham et al. 1995). The maintenance and generation of MHC diversity is quite 
complex; however, it seems the high level of diversity ensures a broad range of immune 
responses to a variety of different pathogens.  
1.4.2. Selection Mechanisms of MHC 
There are two main models that contribute to MHC polymorphism: disease-
based and reproductive mechanisms. Disease based models consist of the heterozygote 
advantage theory, negative frequency dependent selection hypothesis and fluctuating 
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selection theory. The heterozygote advantage theory was first proposed by Doherty and 
Zinkernagel in 1975 (Doherty and Zinkernagel 1975). This hypothesis states that within a 
given population where individuals are exposed to various pathogens, heterozygotes are 
able to present more antigens to T cells than homozygotes, thus heterozygotes are more 
resistant to pathogens than homozygotes (Bernatchez and Landry 2003; Doherty and 
Zinkernagel 1975). Another disease-based model is the negative frequency dependent 
selection hypothesis or rare allele advantage, proposed by Clarke and Kirby in 1966 
(Bernatchez and Landry 2003; Clarke and Kirby 1966). This hypothesis proposes that 
new or rare alleles incur a selective advantage when a novel pathogen strain arises. 
Therefore, the fitness advantage of a rare allele results in positive selection and causes an 
increase in phenotype, while the more common haplotype will decrease in frequency 
(Codner 2010). The last disease based model is the fluctuating selection theory. This 
theory states that MHC diversity is maintained by spatial and temporal heterogeneity in 
the type and abundance of pathogens present and that MHC selection is directional and 
that pathogen flux is determined by the environment (Hill et al. 1991; Spurgin and 
Richardson 2010).  
 Reproductive mechanisms for MHC polymorphism include the disassortative 
mating preferences and inbreeding avoidance theories. The disassortative mating theory 
states that disease-based fitness differences between MHC genotypes would lead to 
reproductive mechanisms favoring high-fitness MHC heterozygotic offspring 
(Bernatchez and Landry 2003; Piertney and Oliver 2006). The inbreeding avoidance 
hypothesis suggests that since the MHC loci is polymorphic, individuals sharing the same 
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MHC alleles are likely to be related. Therefore, matings among related individuals is 
discouraged in order to prevent recessive deleterious mutations (Bernatchez and Landry 
2003). It is also proposed that specific odors produced by an individual is a potential 
marker for relatedness, hence this could be a cue to avoid inbreeding (Bernatchez and 
Landry 2003; Piertney and Oliver 2006).  
1.4.3. Characterizing Polymorphisms of the BoLA Class I Region 
Occurrence of BoLA alleles in a cattle population exposed to pathogens such as 
FMDV can provide insights on particular epitopes, which can ultimately aid in vaccine 
design. Polymorphisms at BoLA class I loci were initially detected using serology (Ellis 
et al. 1998; Spooner et al. 1979). However, molecular techniques such as cloning and 
sequence specific PCR (PCR-SSP) have demonstrated increased BoLA allelic diversity 
within serologically defined haplotypes and improved discriminatory power among 
BoLA allelic polymorphisms (Babiuk et al. 2007; Birch et al. 2006; Ellis et al. 1998). 
This additional data has improved our understanding of BoLA molecules associated with 
serologically defined haplotypes and has allowed for discrimination between BoLA 
molecules (Babiuk et al. 2007; Birch et al. 2006; Ellis et al. 1998). As such, improved 
methods for identifying existing and new BoLA alleles are needed. Recent advances in 
next generation sequencing (NGS) technologies allow for the sequencing of highly 
polymorphic regions of the genome, such as the MHC locus. These high-throughput 
methodologies have been applied to MHC class I typing for several species, such as 
humans, nonhuman primates, and swine, but have been less commonly used in cattle. 
Knowledge of the degree of polymorphism and expression levels of specific BoLA 
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alleles is fundamental to understanding the functional importance of a particular locus. 
Comparison of different BoLA class I typing methods is shown in Table 1-1. 
Table 1-1: Comparison of BoLA typing methods  
Typing Assays 
for BoLA Class I 
Strengths Limitations References 
Serology •High Throughput 
•Inexpensive 
•Lacks specificity at allelic 
level 
•Limited availability of 
antibodies 
•Requires large volumes of 
blood 
•Requires viable lymphocytes 
•Difficult to find good 
antisera for rarer antigens in 
different populations 
•Fresh samples 
(Caldwell et al. 1977; 









•No new allele discovery 
•False Positives  
•False Negatives 
•Negative results are 
ambiguous 
















•Gel to Gel variation 
•Need expertise in the assay 
 
(Davies CJ 1994; Joosten 






•Able to identify 
new alleles  




•Fresh samples not 
needed 




• Labor intensive 
•Only detects polymorphisms 
at restriction sites 
•Does not tell identity of 
polymorphism, just location 
















alleles are present 
•Does not tell identity of 
polymorphism 
(Arguello and Madrigal 






along whole gene 
•Comparing 









•Up to 1kb read 
length 
•Expensive  
•AT rich genes don’t 
sequence well 
Polyhomodimers interfere 




(Babik et al. 2012) 
 
Illumina MiSeq •High Throughput 
•Up to 600 bp read 
length 





1.5. Peptide binding & T cell epitopes 
1.5.1. Peptide binding  
Despite the fact that peptide binding to MHC class I molecules is the most 
selective step in determining immunogenicity of antigens from intracellular pathogens 
such as viruses (Yewdell and Bennink 1999); the diversity of peptide-BoLA binding 
specificity has only been characterized for a limited number of BoLA molecules (Hansen 
et al. 2014). Understanding peptide-BoLA class I binding specificities may facilitate 
development of vaccines or reagents for quantifying the adaptive immune response to 
intracellular pathogens, such as foot and mouth disease virus (FMDV). Polymorphisms in 
the peptide binding region of class I molecules determine peptide binding affinity and 
stability during antigen presentation, which can be measured by biochemical assays (See 
Chapter 2). The peptides that bind to class I molecules often share common features (i.e., 
motifs); this is a function of key amino acid residues in the binding pockets of the MHC 
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molecules. Typically positions 2, 3, and 9 are the critical anchor positions required for 
peptide binding (Rammensee et al. 1995). The antigenic peptides (epitopes) presented in 
the context of MHC class I molecules on the surface of virus-infected cells or activated 
antigen presenting dendritic cells are recognized by TCRs on CD8+ T cells.  
1.5.2. Characterization of T cells 
T cells develop in the thymus from a common lymphoid progenitor and are 
defined by expression of a TCR. The TCR is responsible for recognizing antigenic 
peptides presented by MHC. T cell activation is controlled by a) local antigen 
concentration, b) the threshold number of engaged TCRs as a fraction of a cell’s total 
TCRs, c) the ability of the cell to engage its TCR sequentially and d) the availability of 
co-stimulation (Rothenberg 1996). T cells need two extracellular signals to initiate 
proliferation and differentiation into activated cells known as effector cells. The first 
signal is the binding of peptide-MHC (pMHC) complexes on the surface of APC to the 
TCR. The second signal is provided by co-stimulators such as CD28 and CD80, which 
trigger T cell activation (Malissen et al. 2014). T cell accessory molecules that aid with 
signal transduction are CD3, ς (zeta), CD4 and CD8 (Abbas 2007).  
CD4+ and CD8+ T cells are activated in different ways. Activation of CD4+ T 
cells requires the presence of antigen in the same lymphoid tissue as the CD4+ T cell. 
This is possible due to the circulation of naïve T cells from the blood to the lymphoid 
tissue. A MHC class II molecule of an APC, typically a dendritic cell, must present the 
antigen in order to trigger activation of T cells. CD4+ T cells also require co-stimulation 
by IL-2 and B7 proteins to become activated. Activation of CD8+ T cells also requires 
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antigen recognition, but by MHC class I-associated peptide antigens (Abbas 2007). In 
addition, helper CD4+ T cells can stimulate activation of naïve CD8+ T cells and can 
promote their differentiation into functional CTLs by inducing cytokine expression by 
APCs. For example, activated CD4+ T cells express the CD40 ligand, which binds to a 
CD40 receptor on an APC, causing stimulation of CD8+ T cells (Abbas 2007). Once 
CTLs are activated they can produce perforin, granzymes, IFN-γ, lymphotoxin and tumor 
necrosis factor (TNF), triggering cell death and inflammation (Abbas 2007).  
The affinity of the TCR for pMHC complexes is much lower than that of 
antibodies (produced by B lymphocytes and not discussed in this thesis). The dissociation 
constant (Kd) of TCR interactions with peptide-MHC complexes ranges from 10-5 to 10-
7M (Abbas 2007). This low antigen-binding affinity creates the need for adhesion 
molecules (integrins) to stabilize the binding between the T cell and the APC. The 
interaction between the T cell and the APC initially occurs in the plasma membrane of 
cells containing glycosphingolipds and protein receptors (lipid rafts), which form an 
immunological synapse. Integrins also mediate migration of T cells in response to antigen 
through a series of intracellular signaling events such as: phosphorylation of TCR chains, 
triggering of protein tyrosine kinases and activation of enzymes such as ERK, JNK and 
PKC lead to the upregulation of transcription factors (NFAT, AP-1 and NF-κB). These 
transcription factors act to induce specific gene transcription, leading to differentiation, 
proliferation and effector actions of T cells (Huse 2009). 
There are three main stages of T cell responses. The first stage is initiated in the 
lymphoid tissues; it is known as the expansion phase (Kaech et al. 2002). In this stage, 
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once a naïve T cell encounters an antigen, it proliferates and differentiates into an effector 
T cell (Kaech et al. 2002). Once the effector T cells have successfully cleared the 
pathogen, the majority (>90%) of the remaining effector T cells die; this is the second 
stage, known as the contraction or death period (Kaech et al. 2002). Lastly, the remaining 
T cells can enter the memory phase, where they become stabilized and are maintained for 
long periods of time (Kaech et al. 2002).  
Activated mature dendritic cells are efficient activators of T cells. During the 
first 24 hours after T cells have been activated, CD4+ and CD8+ T cells prepare for 
clonal expansion triggered by IL-2. CD8+ T cell division begins 6-8 hours after initial 
stimulation and CD4+ T cell division occurs 36-48 hours after the initial stimulation. 
This leads to differentiation of the T cells into effector cells or memory cells. In the 
effector phase of the response, CD4+ T cells secrete cytokines, activating macrophages 
and B cells. CD8+ T cells respond by killing the infected cell thru mechanisms such as 
perforin, granzyme and Fas ligand pathways (Groscurth and Filgueira 1998). 
1.5.3. Detection of Antigen-Specific CD8+ T cell Responses 
It is well established that CD8+ T cells play an important role in clearing many 
intracellular pathogens. Recently there has been increased interest in developing 
therapeutic vaccines capable of eliciting or enhancing virus-specific CD8+ T cell 
responses. Human immunodeficiency virus (HIV), hepatitis C virus (HCV), most herpes 
viruses (HSV) and foot and mouth disease virus (FMDV) are examples of pathogens that 
can be resistant to neutralization by antibodies; therefore, T cells play a critical role in 
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clearance and protecting the host from these pathogens (Borrego et al. 2006; Woolard and 
Kumaraguru 2010).  
Great progress has been made over the last decade to address the lack of 
accurate and quantitative assays to detect specific T cell responses (Hadrup and 
Schumacher 2010). A few of the current methods of high-throughput peptide-MHC 
(pMHC) based methods available for CD8+ T cell detection include ELIspot assays, 
tetramers and MHC microarrays (Hadrup and Schumacher 2010). ELIspot and tetramers 
were used in chapter 3 of this dissertation to assess CD8+ T cell responses following 
FMDV vaccination in bovine. These high-throughput methodologies are important for T 
cell epitope identification, monitoring and function. In combination with these 
technologies by using a reverse immunology approach (in silico epitope predictions from 
the sequence of a target gene of interest), is changing the way to verify the identified 
MHC-ligands recognized by T cells (Hadrup and Schumacher 2010). The reverse 
immunology approach has been used in bacterial and viral pathogens, such as 
meningococcus B, human immunodeficiency virus, yellow fever virus, West Nile virus, 
dengue virus, herpes virus, and hepatitis C virus (Bruno et al. 2015; Rappuoli 2001). This 
novel approach has not yet specifically been applied to FMDV in cattle.   
1.5.4. IFN-γ ELIspot Assay 
Antigen specific T cells occur in relatively low frequencies (1/100,000-
1,000,000), which makes identifying them a challenge (Kalyuzhny 2012). The ELIspot 
assay is a highly sensitive technique to detect single bioactive molecule (e.g., cytokine) 
producing cells. If one million PBMCs are plated per well, the lower detection limit of 
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the assay is 0.0001%, which exceeds the detection limit of intracellular cytokine staining 
and tetramers (Kalyuzhny 2012). The ELIspot assay is the gold standard of detecting the 
frequency and function of antigen-specific CD8+ T cell responses (Malyguine et al. 
2012). The use of peptide pools consisting of overlapping peptides facilitates high-
throughput screening, which is an advantage of the ELIspot assay.  
 
Figure 1-3: Illustration of IFN- γ ELIspot assay used in this study. Figure made by author. 
For example, an IFN-γ ELIspot assay was used to detect antigen-specific MHC 
restricted CD8+ T cell responses following FMDV infection or vaccination (Guzman et 
al. 2010; Guzman et al. 2008). In the more recent study, they demonstrated induction of 
IFN-γ release by CD8+ T cells in response to peptide pools, which contained 15 amino 
acids overlapping by 10 amino acids, spanning the P1-2A protein of FMDV serotype O 
UKG/35/2001(Guzman et al. 2010). After further testing of individual peptides in a 
positive peptide pool, one nonamer peptide (YYFADLEVA) produced a statistically 
significant number of IFN-γ producing CD8+ T cells. A schematic of the IFN-γ ELIspot 
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used in this thesis is outlined in Figure 1-3. Numerous other studies have used IFN-γ 
ELIspot assays to quantify the cellular immune responses to pathogens such as 
arenavirus, vaccinia virus, human immunodeficiency virus, cancer, varicella-zoster virus 
and bovine tuberculosis (Assarsson et al. 2007; Botten et al. 2010; Malyguine et al. 2012; 
Smith et al. 2001; Streeck et al. 2009; Vordermeier and Whelan 2012). The importance of 
cell-mediated immunity in protection against the pathogens listed above emphasizes the 
need for highly sensitive detection methods.  
1.5.5. MHC Tetramer Technology 
The recent development of tetramer technology has provided new tools for the 
studies of MHC restricted CD8+ T cell responses. Tetramer technology was developed to 
address the weak interaction (dissociation constants of 10-6 M or less) between the TCR 
and its ligand (Constantin et al. 2002). An MHC tetramer is a complex of four MHC class 
I or II glycoproteins loaded with peptide, bound to a fluorescently labeled streptavidin 
molecule, as visualized in Figure 1-4 (Altman et al. 1996; Klenerman et al. 2002).  
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Figure 1-4: Simplified schematic of MHC class I tetramer (Klenerman et al. 2002). 
The MHC tetrameric complex binds the TCR with greater avidity than a single 
TCR-peptide MHC interaction. The tetramers bind to T cells that are specific for both the 
MHC type and the peptide used in the tetramer. Antigen-specific T cells from immunized 
and challenged animals can be identified by tetramer staining. MHC class II tetramers in 
cattle have been used to enumerate and track T cells during infection or vaccination by 
Anaplasma marginale and Babesia bovis (Norimine and Brown 2005; Norimine et al. 
2006). In swine, Patch et al., (2011) demonstrated FMDV-specific CTL killing and 
confirmation by MHC class I tetramer staining in response to vaccination against FMDV. 
More recently, Svitek et al., (2014) created and validated the first use of pMHC class I 
tetramers in bovine to rapidly identify Theileria parva specific CTL responses. There is a 
need to expand the BoLA tetramer technology to other molecules and epitopes, as this 
will advance the analysis of antigen-specific T cells, thus making it possible to better 
characterize the bovine cellular immune responses. 
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1.6. Foot and Mouth Disease 
Foot-and-mouth disease (FMD) is a disease with severe agricultural and 
economic implications of cattle and other cloven-hoofed animals (Grubman and Baxt 
2004; Lee 2010). The causative agent of FMD is a small (8.5kb), plus-sense, ssRNA 
virus, which belongs to the Aphthovirus genus of the family Picornaviridae (Belsham 
1993). There are seven major serotypes: O, A, C, Asia 1, and South African Territories 
(SAT) serotypes SAT 1, SAT 2, SAT 3. Numerous subtypes occur within each serotype, 
reflecting significant genetic variability, which is a problem for vaccine design (Knowles 
and Samuel 2003).  
1.6.1. Impacts of FMDV 
Over past two decades, formally FMD-free countries have seen outbreaks that 
have raised awareness of the susceptibility of livestock and how rapidly the disease can 
spread (Fevre et al. 2006; Thompson et al. 2002). In 2001 an epidemic of FMD in 
England caused 2,030 outbreaks to occur among livestock and 15 suspected cases of 
human FMD infection were reported. As a result of this epidemic over 4 million animals 
were slaughtered and the UK economy suffered a financial loss of 12-14 billion US 
dollars (Scudamore and Harris 2002; Thompson et al. 2002). All 15 human cases were 
proven negative by reverse-transcription-polymerase chain reaction (RT-PCR) (Turbitt 
2001).  
Outbreaks of FMD continue to be a problem worldwide. In 2013-14 there were 
974 outbreaks of FMD reported to the World Organization for Animal Health (OIE) from 
18 different countries (Agriculture 2015). Approximately 70% of these outbreaks have 
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been resolved according to reports submitted to the OIE (Agriculture 2015).  The world 
map describes the prevalence of FMD based on the reports submitted to OIE (Figure 1-
5).  
 
Figure 1-5: Outbreaks reported to OIE during 2013-14 (Agriculture 2015). 
As shown in figure 1-5, FMD continues to be a threat to the world’s agricultural 
economy. Although the last outbreak of FMDV in the United States was in 1929, it is 
estimated that an outbreak in California alone, would have an economic impact of $2.3-
$69.0 billion dollars (Carpenter et al. 2011).  
1.6.2. Clinical Signs of Disease and Pathogenesis 
FMDV is a systemic disease of domestic and wild cloven-hoofed animal species 
such as: cattle, swine, sheep, goats, buffaloes and camels (Alexandersen and Mowat 
2005). FMD in cattle is characterized by fever (above 104oF), excessive salivation, 
lameness, lesions on the tongue, feet and snout, decreased milk production and general 
morbidity (Alexandersen and Mowat 2005; Klein 2009). The mortality rate is low, but 
the morbidity is high and most animals do not recover to their full production potential 
 23 
(Grubman and Baxt 2004). In swine FMD primarily affects the feet, characterized by 
severe lesions on the coronary band, interdigital clefts and blubs, associated with severe 
lameness (Klein 2009). In cattle, sheep and goats, the disease is less severe, however 
lameness and inflammation at the cloves and mouth do occur (Alexandersen and Mowat 
2005).  
1.6.3. Host Response to FMDV Infection and Vaccination  
FMDV triggers a rapid humoral response in either infected or vaccinated 
animals. Virus specific antibodies protect animals in a serotype specific manner against 
reinfection (Grubman and Baxt 2004; McCullough et al. 1992). The primary antigenic 
site recognized by neutralizing antibodies is a region in the G-H loop (residues approx. 
140-160) of the VP1 protein expressed on the surface of the viral capsid (Bittle et al. 
1982). In addition neutralizing antibodies target epitopes on three external structural 
proteins VP1, VP2 and VP3 (Grubman and Baxt 2004). 7-14 days after infection or 
vaccination strong protective immunity is evident (Grubman and Baxt 2004). IgM 
antibody appears 1st followed by IgG approximately 4-7 days post-infection. In cattle, 
during the early phases of infection, IgG1 is greater than IgG2 and IgA can be detected in 
the upper respiratory tract (Grubman and Baxt 2004; Mulcahy et al. 1990).  
FMDV induces lymphopenia in swine and cattle (Bautista et al. 2003; Diaz-San 
Segundo et al. 2006; Maddur et al. 2008). Lymphopenia affects all B and T cell subsets 
and depletion of lymphocytes is correlated with the onset of viremia (Bautista et al. 2003; 
Diaz-San Segundo et al. 2006). The rapid, but transient, lymphopenia causes a reduction 
in the number B and T cells, adversely affecting T cell function (Golde et al. 2011). 
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FMDV interferes with host protein synthesis and disruption of the secretory pathway 
appears responsible for inhibition of new MHC class I translation and surface expression 
in FMDV-infected cells (Sanz-Parra et al. 1998).  Specifically, a decrease in surface 
expression of MHC I molecules during in vitro FMDV infection suggests that 2B, 2C 
and/or 2BC may be involved in delaying the initiation of host adaptive immune response, 
adversely effecting the secretion of signaling molecules (Grubman et al. 2008).  
Although neutralizing antibodies have been seen as the ideal immune response 
in FMDV infection and are the primary goal of vaccine design, they are not always 
correlated with protection. For example, in carrier animals, live virus can persist in the 
host, despite high titers of neutralizing antibodies (DiMarchi et al. 1986; Juleff et al. 
2008; McCullough et al. 1992). It has been suggested that cell-mediated immunity may 
play an important role in clearing the virus from these persistently infected animals 
(Grubman and Baxt 2004). CD4+ and CD8+ T cells have been shown to induce anti-viral 
responses in mice, swine and cattle following infection and vaccination (Bautista et al. 
2003; Collen et al. 1989; Garcia-Valcarcel et al. 1996; Grubman and Baxt 2004). For 
example, mice vaccinated with a DNA vaccine expressing B and T cell epitopes from 
FMDV structural and non-structural proteins were protected against disease development 
but were not able to induce an FMDV specific antibody response (Borrego et al. 2006). 
This was also the case when both swine and cattle were vaccinated with a replication-
competent human adenovirus 5 (Ad5) vector expressing the VP1 capsid precursor; 
generation of virus specific neutralizing antibodies were not detected in the serum, but 
animals were partially protected from FMDV challenge (Sanz-Parra et al. 1999a; Sanz-
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Parra et al. 1999b). More recently, Patch et al., (2011) demonstrated the induction of 
FMDV specific cytotoxic T cell killing by vaccination in swine and that in the absence of 
significant humoral immunity a killer T cell response could reduce clinical disease and 
decrease viremia in swine challenged with live virus (Patch et al. 2013). Therefore, 
combination of antibody and T cell responses to vaccination might better predict 
protection post challenge (Glass and Millar 1994).  
Despite the prominent ability of CD8 cytotoxic T lymphocytes (CTLs) to kill 
virus infected cells, defining the role of CTLs in FMDV infection has gone largely 
unexplored in cattle, due to technical challenges in establishing assays to measure their 
activity. FMDV is a highly cytopathic virus, which causes infected cells to be rapidly 
lysed in vitro (Grubman and Baxt 2004). Therefore, these cells cannot be used as target 
cells in the CTL assay. In addition the analysis of CTL function requires an assay to 
measure lysis of virus infected target cells in an epitope specific, MHC restricted fashion. 
This is a challenge when faced with the high levels of MHC diversity in an outbred 
population. Only a handful of studies have demonstrated CD8+ T cell MHC class I 
restriction in cattle and swine in FMDV (Gerner et al. 2007; Gerner et al. 2006; Gerner et 
al. 2009; Guzman et al. 2010; Guzman et al. 2008; Patch et al. 2011). Despite a more 
dedicated focus to assess T cell immunity in FMDV, their role and importance in the 
disease are still unclear and should be further investigated.  
1.6.4. Infection and Transmission 
FMDV can spread rapidly in the form of aerosolized droplets, saliva, direct 
animal to animal contact or through indirect contact of personnel or contaminated 
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surfaces (Alexandersen and Mowat 2005). Several factors contribute to the rate of virus 
spread, incubation period and disease severity. These factors include viral dose, route of 
infection, virus strain, host species and husbandry of the animals (Quan et al. 2009). The 
primary route of infection is through the upper respiratory tract and following a natural 
infection in ruminants, initial virus replication takes place in epithelial cells 
(Alexandersen and Mowat 2005; Jackson et al. 2003). The dorsal surfaces of soft palate 
and adjacent nasopharynx are the primary sites of viral entry (Alexandersen and Mowat 
2005). After the initial entry of the virus in vivo the virus spreads to the regional lymph 
nodes and into circulation (Alexandersen et al. 2001). 1-3 days prior to the onset of 
viremia, the virus can be detected in the oral cavity by real-time RT-PCR (Alexandersen 
et al. 2001).  
The route of transmission depends upon the host animal. Cattle, sheep and goats 
can exhale up to 5.2 log10TCID50 of virus per day and pigs can produce 8.6 log10TCID50 
per day, significantly contributing to the source of airborne transmission of FMDV 
(Alexandersen et al. 2002; Klein 2009). According to Hartnett et al., (2007) the most 
common route of spread of FMDV into countries free of disease is the illegal use of 
feeding virus-contaminated food scraps to pigs. The virus can persist in temperatures as 
low as -20oC and is susceptible to changes in pH post mortem in meat, but the lack of pH 
change in the glands and bone marrow allows for virus survival (Kitching 2005). Human 
infection does not seem to have a significant role in the natural infection of FMD. 
However, people and fomites can have a role in passive transfer of the virus from 
infected animals (Alexandersen and Mowat 2005). 
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1.6.5. FMD Virus Genome Organization 
The FMD virion is a 140S particle consisting of single-stranded RNA genome and 
60 copies each of four structural polypeptides, 1A, 1B, 1C, 1D (also known as VP4, VP2, 
VP3 and VP1, respectively), which associate to form an icosahedral shell or capsid 
(Carrillo et al. 2005; Jackson et al. 2003). The FMDV genome structure is comprised of 
an open reading frame (ORF) flanked by highly structured 5’ and 3’ untranslated regions 
(UTRs) (Carrillo et al. 2005). The capsid protects the genome whilst the virus is in transit 
and mediates host interactions (Carrillo et al. 2005; Jackson et al. 2003). FMDV initiates 
infection by receptor-mediated endocytosis, when the Arginine-Glycine-Aspartic Acid 
(RGD) motif within the G-H loop of VP1 binds to cellular integrin receptors (αvβ6, 
αvβ3, αvβ5, αvβ1) on the surface of these cells (Alexandersen and Mowat 2005; Mason 
et al. 1994; Monaghan et al. 2005; Rieder et al. 1994). In cell culture FMDV acquires the 
ability to use other receptors such as glycosaminoglycans, which do not require the RGD 
motif (Klein 2009). After entering the endosome, the acidic pH of this compartment 
causes an uncoating of the viral genome. The viral genome is then translocated across the 
endosomal membrane into the cytosol where it is released and serves as an mRNA 
template for the translation of viral proteins (Grubman and Baxt 2004). One product of 
translation is a polyprotein that is subsequently cleaved by a variety of virus-encoded 
proteases, such as leader Lpro and 3Cpro into mature structural and nonstructural proteins 




Figure 1-6: Representative map of the FMDV genome (Grubman and Baxt 2004). 
1.6.6. Current Control Practices 
In an effort to preserve FMD-free trade status, the primary control measure 
countries use is slaughter (stamping out) of infected and nearby susceptible domestic 
species. OIE regulations require countries that vaccinate to wait a minimum of 6 months 
to regain FMD-free status, as opposed to only 3 months when clearing the outbreak via 
stamping out (Agriculture 2015). Therefore, the prolonged loss of livestock exports and 
products can have devastating effects on a country’s economy. One way to reduce the 
need for such drastic measures is with the use of improved vaccines.  
Inactivated FMD vaccines have been available for more than 70 years. The use 
of vaccines has often been considered a last resort in response to an outbreak in disease 
free countries due to the trade regulations. Limitations of the current FMDV killed virus 
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vaccines include only partial protection and a short duration of immunity (revaccination 
is often required every 4 or 6 months). Virus neutralizing antibodies induced by 
vaccination are not protective across multiple serotypes. Additionally, in order to support 
DIVA (differentiating infected from vaccinated animals) in diagnostic testing for 
outbreak control and surveillance, some vaccine formulations need to undergo additional 
purification steps to remove cellular contaminants as well as some nonstructural viral 
proteins (Gao et al. 2012). Production of the killed virus vaccines also requires the 
growth of large quantities of virus, involving expensive high containment (biosafety level 
3) facilities for manufacture (Doel 2005; Rodriguez and Gay 2011).   
The recent development of a replication defective human adenovirus (Ad5) viral 
vector containing the capsid and 3Cpro coding regions of FMDV has addressed several of 
these limitations. The new vaccine has DIVA capabilities, does not require large amount 
of virus for manufacture and is protective in both cattle and swine (Rodriguez and 
Grubman 2009). It was granted a conditional license for inclusion of the vaccine in the 
US National Veterinary Vaccine stockpile (Grubman et al. 2010). OIE has set the goal for 
global eradication of FMD by the year 2030 and improved FMDV vaccines will be 






My dissertation research hypothesized that increasing our knowledge on the 
BoLA class I diversity in Holstein cattle and together with the translation of current 
technologies to assess T cell responses would lead to a better understanding of the bovine 
adaptive immune response to FMDV. Three ways we addressed this hypothesis was by: 
1) quantify, define and develop methods to detect polymorphisms of the BoLA class I 
genes of Holstein cattle in a restricted population from a commercial purebred 
cooperative-research herd in Vermont, 2) to define the FMDV capsid protein peptide 
repertoire bound by BoLA class I molecules using bioinformatics and biochemical 
affinity and stability assays, 3) demonstrate clonal T cell expansion for specific epitope 
polypeptides using ex-vivo multi-color flow cytometric MHC-epitope complexes 
(tetramers), followed by IFN-γ production measured by an ELIspot assay to quantify and 
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Background: Major histocompatibility complex (MHC) class I molecules are 
polymorphic and polygenic creating challenges for standard genotyping methods 
typically used for other genes of interest. Current techniques for identification of 
expressed MHC class I alleles of cattle are time consuming and costly. Recent advances 
in next generation sequencing (NGS) technologies allow for the sequencing of highly 
polymorphic regions of the genome, such as the MHC locus. These high-throughput 
methodologies have been applied to class I MHC typing for several species, such as 
humans, nonhuman primates, and swine, but have been less commonly used in cattle.  
Results: Herein, we described a comprehensive method for genotyping bovine leukocyte 
antigen (BoLA) class I genes from 28 Holstein cattle by using Illumina MiSeq, cloning 
and Sanger sequencing, and polymerase chain reaction sequence-specific primers (PCR-
SSP). Illumina MiSeq was used to evaluate a 375-bp complementary DNA (cDNA) PCR 
amplicon spanning the highly polymorphic peptide-binding region. Cloning and Sanger 
sequencing was used to determine the 1kb full-length BoLA class I region. Additionally, 
PCR-SSP was conducted for 17 specific alleles for which primers are available. We 
present a streamlined bioinformatics pipeline for analyzing Illumina MiSeq data for 
MHC typing. The pipeline consists of rigorous requirements of sequence quality checks, 
consensus alignments, and de novo abundance based chimera detection. Using this 
Illumina MiSeq pipeline, we can separate true alleles from allelic artifacts, and in 
addition, identify potentially new alleles or variants of existing alleles. A combination of 
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all three different platforms, Illumina MiSeq, cloning and Sanger sequencing, PCR-SSP, 
will help capture the total allelic profile of an individual animal.  
Conclusions: Illumina MiSeq amplicon sequencing is a higher-throughput and higher-
resolution assay for efficient BoLA genotyping. While Illumina MiSeq provides a viable 
alternative to known methods, quality checking with stringent requirements is needed to 
differentiate artifacts from true alleles. This approach provides an alternative method for 
genotyping BoLA and improves our understanding of the genetic specificity of BoLA. 
Key Words: Major histocompatibility complex; BoLA; Illumina MiSeq sequencing; 
genotyping; cattle   
2.2. Background 
The immune system plays a critical role in the maintenance of individual animals 
and overall herd health. The major histocompatibility complex (MHC) is a highly 
polymorphic region that allows the body’s immune system to differentiate pathogen-
infected cells from healthy cells. Expanding knowledge on which peptide epitopes bind 
particular MHC molecules could influence epitope discovery and vaccine design. MHC 
polymorphism is influenced by gene duplication, copy number variation, recombination 
and pathogen selection pressure [1-4]. As such, cattle MHC, also known as the bovine 
leukocyte antigen (BoLA), are one of the most polymorphic gene regions found in cattle 
[3]. In bovine, three BoLA classes exist; class I, II and III, each having a specific role in 
immune function. BoLA class I and II both play a role in antigen presentation, whereas 
the function of BoLA class III has been associated with components of the complement 
system [3, 5]. BoLA class II molecules present exogenous peptides to CD4 T-
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lymphocytes, while BoLA class I molecules present endogenous peptides to CD8 T-
lymphocytes [6]. The present study is focuses on developing methods to rapidly 
characterize BoLA class I diversity, an important first step in order to study the BoLA 
restricted immune response following infection or vaccination.  
 Cattle, pigs, horses and sheep, express a variable number and combination of 
class I MHC genes [7-9]. Cattle have six classical class I genes, 1-3 of which are 
typically expressed in an individual animal. There are currently 114 BoLA class I alleles, 
including 95 classical alleles, and 19 non-classical alleles in the Immunopolymorphism 
database [IPD-MHC; http://www.ebi.ac.uk/ipd/mhc/bola/], a database of validated MHC 
sequences [10]. These sequences represent the known allelic diversity of cattle. Over 
40% of the BoLA sequences in IPD-MHC are from Holstein cattle. The IPD-MHC 
database also contains details regarding BoLA nomenclature, breed type, and serological 
specificity, but it is not possible to rapidly conduct searches based on these factors 
directly through the available interface. Additional tools are needed to better explore the 
information in this database, especially as the size of the database is expected to increase 
with the discovery of new alleles.  
A variety of methods have been used to identify polymorphisms in BoLA alleles. 
Initially, polymorphisms of the BoLA locus were detected through use of alloantisera in 
complement-dependent microcytotoxicity assays [11, 12].  More recently, the use of 
molecular techniques such as recombinant DNA technology (cloning), chain-termination 
Sanger sequencing, and polymerase chain reaction using sequence specific primers 
(PCR-SSP) has increased the number of known BoLA alleles. The new data has changed 
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our understanding of BoLA molecules associated with serologically defined haplotypes, 
and improved the power to discriminate between BoLA molecules [4, 11, 13]. As such, 
improved methods for identifying existing and new BoLA alleles are needed. In cattle, 
the potential combination of diversity within a population and between regions is not as 
well characterized as humans. This leads to potential bias of BoLA alleles in the curated 
database. For example, the current IPD-MHC database is principally based upon 
European samples, which may not represent class I sequences from North American 
cattle, as genome wide differences have been found between the two populations [14]. 
Knowledge of the degree of polymorphism and expression levels of specific BoLA 
alleles is fundamental to understanding the functional importance of a particular 
molecule.  
Recently, next generation sequencing technologies (NGS) has been used for high-
throughput MHC genotyping in several species including humans, macaques, bison and 
swine [8, 15-19]. NGS technology can rapidly improve detection of rare sequences, 
expand information on haplotypes and allow for better understanding of inter-species 
variation and differences by geographic region [17, 18, 20]. To date, these techniques 
have not yet been widely used in cattle. The goal of the present study is to explore the 
utility of Illumina MiSeq (MRDNA, Shallowater, TX), as a tool for rapid BoLA 
genotyping. This method is capable of providing up to 500 bp read lengths, with more 
than 8 GB of data in less than 40 hours [21]. The Illumina MiSeq system uses the 
principles of sequencing by synthesis technology. This technology allows for a massively 
paralleled system for tracking the addition of labeled nucleotides as the DNA chain is 
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copied [15]. The advantages of NGS include the ability to scale up genotyping projects 
for larger sample sets, at a fraction of the cost, in a short period of time. Disadvantages of 
NGS include short read lengths, presence of indels, complications of de novo assembly, 
errors associated with GC rich sequences, and difficulty in establishing efficient 
procedures for distinguishing true alleles [15, 22]. Despite these limitations, NGS 
technology is rapidly evolving and its use in other species provides support that this 
technology could be applied to cattle.   
Here we describe the use of Illumina MiSeq NGS technologies as a high-
throughput platform for comprehensive and rapid MHC class I genotyping of Holstein 
cattle. Illumina MiSeq results were compared to the more traditional MHC typing 
methods of 1) PCR-SSP and 2) cDNA amplicon cloning and Sanger sequencing. Our 
results suggest that Illumina MiSeq in combination with a streamlined bioinformatics 
workflow will allow for rapid identification of existing and potentially new BoLA class I 
alleles.   
2.3. Materials and Methods 
2.3.1. Animals and sample collection  
Whole blood samples were collected from 28 purebred Holstein steers by jugular 
or caudal tail venipuncture using sodium heparin vacutainer tubes (BD Bioscience, San 
Jose, CA) in accordance with Institutional Animal Care and Use Committee (IACUC) 
protocol #10-026. Steers were housed at the Miller Research Farm at the University of 
Vermont (UVM) Dairy Center of Excellence (DCE). Samples were transported and held 
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on ice until peripheral blood mononuclear cell (PBMC) isolation and mRNA extraction 
could be performed (within two hours of blood collection).  
2.3.2. RNA Extraction and cDNA synthesis  
RNA extraction and purification from isolated PBMCs was conducted using a 
TRIzol Reagent (Invitrogen, Grand Island, NY) and RNeasy mini kit (Qiagen, Valencia, 
CA), according to manufacturer’s instructions, with minor modifications. Briefly, whole 
blood was centrifuged at 3,600 x g for 15 minutes at 4°C, for isolation of the lymphocyte 
monolayer. The monolayer (150 µL) was then pipetted off and added to 1 mL of TRIzol 
reagent and incubated for 1 minute. Ice-cold chloroform (200 µL) was added to the 
mixture and incubated for 1 minute and centrifuged at 1500 x g for 15 minutes at 4°C. 
The aqueous layer (400 µL) was combined with ice-cold ethanol (400 µL) and added to 
the RNeasy column. After DNase digestion manufacturer’s instructions were followed. 
RNA samples were eluted from the column and stored at -80°C. cDNA was synthesized 
from these samples within a week of extraction using the Promega ImProm-II Reverse 
Transcription System, as per manufacturers’ methods.  
2.3.3. PCR-SSP  
PCR-sequence specific primers (SSP) were used in accordance with previously 
published methods [11, 23] to amplify a total of 17 known alleles. A total of 81 steers 
were screened by PCR-SSP; based on these initial results, we selected 28 animals for 
cloning because they expressed one or more alleles of interest for parallel vaccine studies 
(1*01901, 2*00801, 2*01201, 3*01701 and 4*02401). 
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2.3.4. Cloning and Sanger sequencing  
cDNA samples from 28 steers were used in the cloning of expressed MHC class I 
genes. Cloning was performed according to protocols outlined elsewhere [13] with one 
exception; a different set of primers was used for generating amplicons from the cDNA 
sample templates. The cDNA samples were amplified using full-length MHC class I 
sequence using “universal primers”, ILRI forward (5’-ATGRGGCCGCGARCCCT-3’) 
and ILRI reverse (5’-TCAMACTTTAGGAACCGTGAGAG-3’) (N. Svitek, personal 
communication). Amplified DNA was separated via a 1.5% agarose gel. The ~1,100 bp 
DNA band of interest was excised from the gel and purified using Qiaquick® gel 
purification kit (Qiagen, Valencia, CA). Purified amplicons were ligated onto a blunt-end 
TOPO cloning vector (Invitrogen, Grand Island, NY) following manufacturer’s 
instructions, transformed using competent Escherichia coli and plated on LB Agar plates 
with 50µg/mL kanamycin (Teknova, Hollister, CA) to screen for competent clones using 
antibiotic resistance. Twenty-four positive clones for each steer were isolated and the 
insert was amplified using flanking primers, M13 forward and M13 reverse. Sanger 
sequencing was conducted on amplicons generated from up to 20 individual clones per 
steer, using a Big Dye Terminator v3.1 (Applied Biosystems) and cycle sequencing 
chemistry at the UVM cancer center DNA analysis facility. In accordance with previous 
studies and cost restrictions, up to 20 clones from each animal was sequenced [13]. 
Forward and reverse sequences were generated and aligned to create consensus 
sequences using Sequencher® version 5.0 (Gene Codes Corporation, Ann Arbor, MI). 
Consensus sequences were subsequently imported into GeneiousPro® version 6.1.8 
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(Biomatters, Auckland, NZ) and compared to known alleles using NCBI basic local 
alignment search tool (BLAST) and the IPD-MHC database for confirmed sequences 
[http://www.ebi.ac.uk/ipd/mhc/bola/].    
2.3.5. Illumina MiSeq library generation and sequencing  
Samples for Illumina MiSeq sequencing were generated from a 410 bp amplicon 
of the hyper-variable region spanning exons two and three (α-1 and 2) of the class I gene 
using “universal primers” bov 7 and bov 11 [4]. Samples were shipped overnight to 
molecular research DNA laboratories (MRDNA, Shallowater, TX), for Illumina MiSeq 
using a 500 cycle MiSeq reagent kit version 2.0.  Unique DNA barcodes were annealed 
to amplicon DNA from each sample to allow for sample source identification throughout 
the process. Samples from 28 animals were multiplexed into a single sequencing run, 
divided into two lanes on the flow cell. Multiplexed samples were purified using 
calibrated Ampure XP beads (New England Biolabs, Ipswich, MA). The purified, 
barcoded samples were used to prepare a DNA library, following Illumina TruSeq DNA 
library preparation protocol (MRDNA, Shallowater, TX). Sequence data was processed 
by binning individual barcodes for each sample (steer number), and aligning amplified 
sequences to all known sequences from the IPD-MHC database. During this process 
several steps were taken to ensure accuracy and to develop a streamlined bioinformatics 
pipeline: 1) Paired end sequences were de-multiplexed; 2) only those reads with an 
average Phred score of Q25 [24] were included, 3) a perfect overlap between forward and 
reverse reads was required to create a consensus sequence; 4) merged reads needed to be 
exactly 418 bp in length, consisting of the barcode (8 bp), forward and reverse primers 
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(35 bp), and bov 7 and bov 11 region (375 bp). These merged sequences were trimmed to 
just the amplicon region (375bp) and then grouped and counted by using Bioawk [25] 
(https://github.com/lh3/bioawk). Only those reads with a minimum threshold of 100 reads 
per sample were included; 5) the resulting clusters were checked for chimeras using 
VSEARCH version 1.0.16 (https://github.com/torognes/vsearch, 10.5281/zenodo.15524) 
de novo assembly, which uses abundance as a reference. VSEARCH default parameters 
were used, with the exceptions of adjusting the minimum score to 1.2 and minimum 
divergence score to 1.5 for chimera detection. Based on this criteria, any sequence 
classified as a putative new chimeric sequence were removed from further analysis; 6) 
Non-chimeric sequences were aligned to the reference file containing BoLA sequences 
from IPD-MHC; 7) Putative new alleles that were not 100% match to the reference 
database were compared across sequences from the steers. Sequences were only 
considered as “new” if the sequence occurred in three or more steers.  
2.3.6. Ruby script and Shannon diversity plot 
A Ruby script was developed to access and manipulate data contained within the 
bovine IPD-MHC (Available at https://github.com/MitalGitHub/IPD_MHC and 
http://asci.uvm.edu/labs/barlow/tools.html). The script allows a search through the BoLA 
class I alleles in IPD by allele name, serological specificity, or breed. The script utilizes 
Ruby gems, such as Bioruby [26], to obtain the nucleotide or amino acid FASTA files 
associated with the search. Sequences downloaded from IPD-MHC were compiled for the 
MiSeq reference file. A Shannon diversity plot was generated using sequences 
downloaded from IPD-MHC and Protein Variability Database server [27].  
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2.3.7. Data analysis 
Analysis of sequences and primer site variation was performed using Geneious 
6.1.8 (Biomatters, Auckland, NZ). Data generated from all platforms were gathered, 
stored and manipulated using Excel (Microsoft). All scripts used in this study are 
available at https://github.com/MitalGitHub/IPD_MHC. Analysis and comparison of all 
three methods was analyzed in Excel.   
2.4. Results 
Three techniques were used to assess MHC class I sequence diversity in 28 
Holstein steers: 1) PCR using sequence specific primers, 2) cDNA amplicon cloning 
followed by Sanger sequencing and 3) Illumina MiSeq amplicon sequencing.  
2.4.1. PCR-SSP  
 Fifteen of the 17 alleles were detected by PCR-SSP (Table 2-1). 6*01301 and 
6*04101 were not found in any of the steers by PCR-SSP. The number of alleles found 
positive by PCR-SSP varied between 2-7 for a given animal.  
2.4.2. Cloning and Sanger sequencing  
 We obtained full-length sequence from 650 clones obtained from the 28 steers. 
The most common allele found by cloning and Sanger sequencing was 1*01901, present 
in 78% (22/28) of the animals (Table 2-1). The other alleles of interest for the parallel 
peptide binding studies were found less frequently by this method: 2*00801 (18%), 
2*01201 (0%), 3*01701 (22%), and 4*02401 (29%) (Table 2-1). The low frequency of 
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these alleles by cloning and Sanger sequencing led to investigation of the ILRI primer 
binding sites, primarily to identify if poor binding here could be the reason for decreased 
numbers of alleles found (Table 2-2). The 30 alleles listed in Table 2-2 were chosen for 
exploration because they were found by either PCR-SSP or Illumina MiSeq. For 
example, a sample with a positive result by PCR-SSP along with high number of ILRI 
primer mismatches and negative result by cloning indicates that there is the possibility of 
false negatives due to preferential selection using this method. While it does not account 
for every instance of discordance between PCR-SSP and cloning results, or Illumina and 
cloning results, there appears to be a strong trend between the number of mismatches in 
the ILRI forward primer and frequency by cloning. One example of this was shown with 
2*01201, there are a total of six mismatches in the ILRI forward primer with this allele 
(Table 2-2). This could be a possible explanation as to why this allele was not found by 
cloning. There were no significant differences (more than one mismatch) between allelic 
and primer sequences in the ILRI reverse region, so this is not likely to be an issue (data 
not shown). Another example of discordance between Illumina MiSeq and cloning is 
shown with 2*00801. This allele was found 23 times by Illumina MiSeq, but was found 
only five times by cloning. Again, this allele has a relatively high number of mismatches 
in the ILRI forward primer, which could explain why it was not found.  
2.4.3. Illumina MiSeq 
 Illumina MiSeq version 2.0 sequencing was performed on amplicons generated 
by bov 7 and bov 11 PCR. Bov 7 and bov 11 primers were chosen as they bind highly 
conserved sites, flanking the most highly polymorphic region within the MHC class I, 
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and were used to generate universal α-1 and 2 amplicons from cDNA templates for NGS 
(Figure 2-1). The average number of reads per sample from Illumina MiSeq was 33,844. 
Further analysis of bov 7 and bov 11 binding regions was performed in silico, and 
revealed a high number of polymorphisms in these regions (data not shown). MHC class 
I sequences were downloaded from the cattle IPD-MHC database using a Ruby script, 
and a reference file for read alignments was created. Several alleles are identical in the α-
1 and 2 regions, therefore, these were combined under the same name in the reference file 
(Table 2-3).  
2.4.4. Comparison of platforms  
The Illumina MiSeq results for the 28 animals that were tested across all 
platforms were compiled and compared to results from both PCR-SSP and cloning and 
Sanger sequencing (Table 2-4). A total of 450 sequence reads conformed to our initial 
quality criteria. However, after passing the sequences thru the VSEARCH program, 181 
of those sequences were classified as chimeric and removed from further analysis. The 
median percentage of chimeric reads per sample (steer) was 29%. As a result 269 
individual sequences passed all stringent requirements set in our pipeline. Using these 
criteria, a range of 1 to 11 alleles per sample were found as a perfect match to a 
previously known allele. The number of positive reads per sample meeting the quality 
criteria varied greatly, from 115 to 100,952 (Table 2-4). This suggests there may not be a 
relationship between the number of positive reads and success of allele calling, as even 
those samples with a lower total read number had 100% matches to known alleles. This is 
important to consider when developing a bioinformatics pipeline, as discarding samples 
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with a low number of reads may lead to false negatives. The summary of the alleles for 
each sample is shown in Figure 2-2. All 28 steers had at least one of the target alleles: 
1*01901, 2*01201, 2*00801 3*01701, and 4*02401. However, 1*01901 was only found 
by Illumina MiSeq in one steer (steer 182) (Figure 2-2). As demonstrated in Figure 2-2, it 
appears some alleles are found at a higher proportion of reads as compared to others. For 
example, 2*00801 was found with an average of 7,469 reads as compared to 2*01801 
was found with an average of 2,555 reads. Illumina MiSeq was able to capture some 
alleles that were missed by PCR-SSP and cloning. For example, for steer 176 we found 
2*01601 by Illumina MiSeq, but when screened by PCR-SSP and cloning this allele was 
not found (Table 2-1 and 2-4). Another example of this is shown in steer 65, Illumina 
MiSeq found 3*00201, but this allele was not found by the other two methods. 
Additionally, Illumina MiSeq was able to find four alleles: 3*03601, 3*03701, 
NC1*00501 and NC1*00201 that were not found by cloning and for which PCR-SSP 
primer pairs are not currently available. However, seven alleles: 1*02001, 1*02101, 
3*01702, 6*01401, 6*01501, NC1*00301 and NC3*00101 were not found by Illumina 
MiSeq, but were found by cloning or PCR-SSP (Table 2-1). We applied the stringent 
requirements from our bioinformatics pipeline to classify potentially new alleles. In order 
to be classified as a potentially new allele, the exact sequence had to meet all quality 
filters, chimera checkpoints and had to be found in at least three different animals. Based 
on these criteria Illumina MiSeq was able to identify 41 potentially new alleles or allelic 
variants based on the α-1 and 2 regions we sequenced. Since only full-length sequence is 
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accepted to IPD-MHC, in order to characterize a new alleles or variants additional work 
needs to be done to validate these sequences.  
2.5. Discussion 
Efficient and reliable genotyping is a prerequisite for understanding the role of 
MHC in the immune response after vaccination or infection. Successful BoLA 
genotyping of large herds depends on robust amplification, high quality sequence reads, 
and rapid analysis workflows. There are several challenges that are presented by the 
current MHC class I typing methods compared in this paper. First, allelic identification 
by PCR-SSP is limited by the available number of PCR-SSP primers, and new primer 
sets need to be designed for any additional alleles of interest. In the IPD-MHC database 
there are over 100 BoLA class I alleles, and this number is likely to grow over time as 
new alleles and variations are discovered. Development of sequence specific primers for 
every allele currently in the database and each subsequent new allele does not seem 
feasible. Second, PCR-SSP does not allow for the discovery of new alleles or variants. 
Third, PCR-SSP testing of individual alleles using separate primer sets is low-throughput. 
Therefore, an alternative method for MHC typing cattle is the use of molecular cloning. 
This method allows for the amplification of full-length MHC sequences (approximately 
1kb), using “universal primers”. Cloning is generally considered advantageous compared 
to PCR-SSP, since the full-length sequences allow for a more complete representation of 
allelic diversity within a herd, as one is not constrained to the specific primers chosen for 
allelic testing. However, cloning is quite costly and a labor intensive process and was 
limited by the number of clones sequenced as shown in this study and others [13, 22]. 
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Another potential flaw of this methodology is the use of “universal primers”, which can 
lead to amplification bias causing certain alleles to be missed (Table 2-2). Currently, for 
submission of a new BoLA allele to IPD, only full-length sequence determined by 
cloning and Sanger sequencing is accepted. However, Illumina MiSeq has the potential to 
identify additional new sequences, but these sequences would need to be further validated 
by cloning and Sanger sequencing at this time. There are merits to each typing system, 
but in a study such as this where the goal is to quickly assess the allelic background of the 
herd as well as build upon existing data, previous methodologies are lacking. Neither of 
the two existing platforms, PCR-SSP nor molecular cloning, present researchers with a 
true “gold standard” for comparison and as such are lacking as diagnostic tools. 
Recently, NGS has been used for MHC genotyping for a number of species such 
as humans, macaques, bison, guppy and swine [8, 15-19, 28]. For the characterization of 
BoLA class I variation in our Holstein cattle population we used bov 7 and bov 11 
primers, which were previously designed to amplify the majority of BoLA class I 
sequences spanning exons 2 and 3 [4, 29, 30]. These primers were also applied in 454 
pyrosequencing to genotype the variation in European bison [19]. Exon 2 and 3 encode 
for the highly polymorphic α-1 and 2 domains composing the peptide-binding groove of 
the MHC class I molecule. This region is not only the most variable and important in 
antigen presentation, but allows for 92% discrimination among the known BoLA alleles. 
Therefore, we focused our efforts specifically targeting this region to determine the 
allelic diversity in cattle using the Illumina-MiSeq system. We validated the NGS 
approach of Illumina MiSeq for MHC class I typing in cattle by comparing the results 
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generated to previous typing methods. This experiment has laid the foundation for 
establishing a NGS MHC genotyping protocol in cattle; however, there are several 
limitations that must be addressed before it can be used as a “stand alone” platform for 
large-scale herd or population level MHC typing. Such limitations include: determining 
the number of polymorphisms or single nucleotide polymorphisms (SNPs), distinguishing 
chimeras from true alleles, and creation of an absolute read threshold for identifying 
expressed genes. In addition to addressing the feasibility of Illumina MiSeq, several 
issues within each of the typing platforms were discovered and explored.    
Cloning and sequencing expressed genes has limitations for large-scale 
population genotyping. Possible preferential amplification of alleles, mismatches between 
primer and target sequences, and cost are all issues associated with this platform. A major 
limiting factor is the number of clones that can be sequenced in a single run. In this study 
the goal was to sequence at least 20 clones per animal, as this number could be readily 
extracted in a single run and fit on one sequencing plate to limit costs. However, this 
practice may affect the probability that all expressed alleles are present among the clones 
selected for sequencing. If we consider only sequencing results from clones in this study, 
our results appeared to conflict with previous published allele combinations in known 
haplotypes [1, 3]. For example, the alleles 1*01901 and 2*00801 are reported to be co-
expressed in all animals of the common haplotype A12, which was confirmed by PCR-
SSP typing for each individual steer enrolled in this study. However, by cloning the allele 
2*00801 was only found in five steers; whereas 1*01901 was identified in 22 animals. As 
previously discussed, many of the alleles presumed to be in our population have at least 
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one mismatch to the forward cloning primer, and for 2*00801 there are five mismatches. 
In addition to sheer number of primer mismatches, many of these occur at the 3’ end of 
the primer sequence, which would likely impair annealing of the primer sequence and 
subsequent amplification of those alleles. We suspect this leads to the preferential 
amplification of those alleles with either perfect matches or a low number of mismatches 
to the primer, and biased our cloning results in favor of those molecules. Additional 
research is needed to identify alternative primers that might be used for cloning full-
length sequences. For example, Birch et al. previously reported using a combination of 
primer pairs for cloning full-length expressed sequences in British Friesian and Holstein 
cattle [4]. However, our prior experiments with these primers were unrewarding (M. 
Pandya, unpublished). 
Similarly, several alleles were not found by Illumina MiSeq (Table 1). Using the 
same haplotype example, A12, 2*00801 was found in every sample it was predicted to 
appear in, but 1*01901 was only found in one steer by Illumina. Mismatches in the bov 7 
and bov 11 primer sequences could lead to decreased binding affinity during the PCR 
methods. It is unknown as to what may be missed by these reactions due to poor 
specificity of these “universal primers” and presents an issue faced by any amplification 
process.   
Additionally there were nine alleles that shared overlapping sequence identity in 
the peptide binding groove of the MHC molecule (Table 2-3). We presume these alleles 
are similar in function, however this is yet to be determined. In order to distinguish 
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between these alleles, additional targeted PCR of the full length BoLA region would need 
to be performed.  
Other potential issues with Illumina MiSeq amplicon sequencing have been 
reported. Several sources have noted the presence of chimeric sequences in high-
throughput sequencing data [22, 31]. Chimeras can be generated during PCR 
amplification when there is incomplete extension of a sequence, which then anneals to 
another “parent” sequence during the next round of the reaction. Chimeras can also be 
generated during the de novo assembly process.  In order to address these issues, the 
VSEARCH program was used to detect putative chimera sequences, however the 
parameters need to be adjusted to identify these sequences correctly. For example, alleles 
3*01701 and 3*00201 were initially classified as chimeric sequences by the VSEARCH 
program, even though the reads were a 100% match to the reference alleles. This 
highlights the need for an optimized bioinformatics pipeline for BoLA molecules 
specifically, as following the default parameters would result in loss of data. In this case, 
we were able to manually classify these sequences as non-chimeric because they could be 
verified by other typing methods. Another potential solution of dealing with chimeric 
sequences and potential artifacts is to optimize the PCR cycles during the library 
preparation steps [32].  
One potential concern that arose after analysis of the Illumina MiSeq data is that 
we observed some steers had more alleles (up to 11) than previously reported in the 
literature. In our streamlined bioinformatics pipeline, we required reads to have a 
minimum threshold of 100 reads per sample. Based on these criteria, for example, steer 
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182 has 11 alleles (Table 2-4) identified by Illumina MiSeq. However, many of these 
alleles had relatively low sequence reads. Increasing the read threshold to 200 reads 
would reduce the number of predicted alleles in a sample, but it is not clear whether by 
shifting the read threshold we would be eliminating sequencing artifacts or true expressed 
sequences. For example, in steer 182 both 1*01901 and 1*03101 were found at <200 
reads per sequence, yet 1*01901 was found by all 3 typing methods in this steer, and 
1*03101 was only found by MiSeq amplicon sequencing. However, following the 
assumption that artifacts should be rarer among individual’s reads than most true alleles, 
increasing the threshold will indeed result in less artifacts [33], although in some cases 
possibly at the expense of eliminating true alleles. Additional experiments are required to 
resolve some of these challenges if NGS is to be applied to BoLA typing.   
In addition to the challenges faced with NGS Illumina platform, important issues 
with the two established methods were also raised. Characterization of primer 
polymorphisms and preferential selection allow past and present results to be viewed with 
a more critical lens. The problem with every system is the challenge of optimizing high 
sensitivity and specificity in each assay. In PCR-SSP we lack primers for every known 
allele and therefore cannot test all 114 known BoLA class I alleles or discover potential 
new alleles or variants. In cloning and Illumina the primers that we select influence 
which alleles get amplified (Table 2-2). Another challenge in the Illumina system is 
determining where to set the appropriate read threshold cutoff in order to reduce the 
number of false positives.  Seven alleles were found by the other 2 methods, but not by 
Illumina MiSeq (Table 2-1). NC1*00301 was not specifically found by Illumina MiSeq 
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because it was identical in the amplicon region to NC1*00201 (Table 2-3). Two 
additional alleles (6*01301 and 6*04101) were not found by any genotyping method we 
used.  
Despite these limitations, Illumina MiSeq allowed for identification of more 
alleles compared to PCR-SSP protocols and is not limited by the number of clones 
produced, all in a single run. The Illumina MiSeq system had far fewer “misses” than the 
other two platforms and provides the best overall coverage of our population (Table 2-1). 
There is far less time spent on sample preparation, far fewer resources consumed, and a 
much faster analysis time once the initial bioinformatics workflow is established. Per-
sample cost for Illumina does vary depending on the level of multiplexing and other 
factors, such as sample and library preparations, but on average is estimated at ~$75-
$100 per each sample. Illumina has higher throughput and higher resolution than PCR-
SSP, cloning and Sanger sequencing.  It is possible that the most comprehensive account 
of genetic expression in a population could be gathered by a combination of methods, 
rather than a single method. For example, our data suggests combining Illumina 
sequencing and PCR-SSP results is a tractable alternative. When used in parallel the two 
methods appear to provide a complete picture in a relatively short time frame, as initial 
high-throughput results could guide PCR-SSP testing, limiting the number of individual 
reactions that would need to be performed. Utilizing the strengths of different high-
throughput sequencing platforms is another option, as a combination of two different 
NGS platforms (Roche 454 and Illumina MiSeq) were used to discover novel full-length 
MHC class I alleles in rhesus macaques [34].   
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2.6. Conclusions 
The recent development of NGS technologies have rapidly increased knowledge 
on human MHC alleles while in bovine, the use of NGS for MHC genotyping is just 
being developed. Despite some challenges, the present study demonstrated Illumina 
MiSeq maybe an efficient high throughput genotyping platform for amplicon sequencing 
of complex multilocus systems such as bovine MHC. This study demonstrated that 
Illumina MiSeq provides a robust, cost effective, alternative to known methods, however, 
stringent quality checking is required. The ability to rapidly and comprehensively 
genotype BoLA within a herd will allow for identification of allele specific BoLA 
peptide binding motifs. Therefore, this will provide to a better understanding of the 
BoLA restricted immune response by studying peptide-BoLA interactions and ultimately 
improve epitope based vaccine design.  
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2.12. Figures and tables 
 
Figure 2-1: Shannon Diversity Plot of the BoLA gene aligned to linear representations of the gene. 
The 410 base-pair (bp) amplicon generated by the bov 7 and bov 11 primers for Illumina MiSeq is 




Figure 2-2: A comparison of MHC class I allele sequences across 28 steers generated from Illumina 
MiSeq. Reads that were <100% match to alleles in the reference file were summed and classified as 
“not 100% match” (shown in gray). Individual alleles displayed as single colors were 100% match to 






















































































Figure 2 Summary of alleles found by Illumina MiSeq  















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3 Alleles containing identical sequence in α1-α2 region, combined in the reference file
2*00601 1*00602 = 2*00601
2*01601 2*01602 = 2*01601
2*01801 2*01802 = 2*01801
2*02601 2*02603 = 2*02601
2*00801 2*00802 = 2*00801
3*00101 3*00102 3*00103 = 3*00101
3*00402 3*05301 = 3*00402
NC1*00201 NC1*00301 = NC1*00201
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Table 2-4: Illumina MiSeq results compared across platforms 
Table 4 Illumina MiSeq results compared across platforms  
Steer ID BoLA allele Read counts  PCR (Y/N) Cloning (Y/N) 
11 2*02201 14176 Y Y 
  2*02601 16026 N/A N 
  3*02702 17753 N/A Y 
31 2*00801 5740 Y Y 
  2*01601 6593 Y N 
  6*01402 1659 Y Y 
  NC1*00201 2072 N/A N 
55 2*00801 8189 Y N 
  2*01601 8717 Y N 
  6*01402 2175 Y Y 
  NC1*00201 3493 N/A N 
56 2*01601 3346 Y Y 
  2*01801 1214 Y N 
  3*01701 8849 Y Y 
  6*01402 932 Y Y 
  NC1*00201 730 N/A N 
59 1*00901 6208 N/A N 
  2*00801 2389 Y Y 
  4*02401 3934 Y Y 
60 2*00801 15690 Y Y 
  NC1*00201 1289 N/A N 
61 2*00801 5252 Y N 
  2*01601 5915 Y Y 
  6*01402 1818 Y Y 
  NC1*00201 1814 N/A N 
62 1*02301 13346 Y N 
  2*00801 4525 Y N 
  4*02401 7765 Y Y 
  NC1*00201 424 N/A N 
  NC1*00501 607 N/A N 
63 2*00801 4704 Y N 
  2*01801 2933 Y N 
  3*01701 17249 Y Y 
65 2*00801 8987 Y N 
  2*01201 5799 Y N 
  3*00201 54155 N N 
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  NC1*00201 460 N/A N 
67 2*00801 3469 Y N 
  2*01801 1389 Y N 
  3*01701 8330 Y Y 
71 1*03101 21159 N/A N 
  2*00801 9992 Y N 
  2*03201N 9996 N/A N 
  NC1*00201 1052 N/A N 
72 2*01201 3199 Y N 
  2*01801 1306 Y N 
  3*00201 36240 N Y 
  3*01701 7586 Y Y 
  NC1*00501 460 N/A N 
73 1*00901 11683 N/A Y 
  2*01801 2373 Y N 
  3*01701 15291 Y Y 
  4*02401 7248 Y Y 
  NC1*00501 627 N/A N 
111 1*03101 16617 N/A Y 
  2*00801 3715 Y N 
  2*03201N 5811 N/A Y 
  NC1*00201 186 N/A N 
117 1*02301 191 N N 
  1*03101 15240 N/A N 
  2*00801 3522 Y N 
  2*03201N 4596 N/A Y 
  NC1*00201 284 N/A N 
134 1*02301 189 N N 
  1*03101 20602 N/A Y 
  2*00801 3710 Y N 
  2*03201N 11428 N/A Y 
  3*00201 694 N N 
  NC1*00201 247 N/A N 
144 1*03101 10147 N/A N 
  2*00801 1996 Y N 
  2*03201N 3078 N/A Y 
154 1*00901 11091 N/A Y 
  1*02301 216 Y N 
  2*00801 1940 Y Y 
  4*02401 6531 Y Y 
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156 1*02301 19811 Y Y 
  1*03101 153 N/A N 
  2*00801 1473 Y N 
  4*02401 4656 Y Y 
169 1*03101 280 N/A N 
  2*00801 10374 Y N 
  2*01801 6115 Y N 
  3*00201 956 N N 
  3*01701 57220 Y Y 
  NC1*00201 237 N/A N 
174 1*02301 171 N N 
  1*03101 303 N/A N 
  2*00801 59252 Y N 
  2*03201N 177 N/A N 
  3*00201 1045 N N 
  3*03601 237 N/A N 
  3*03701 944 N/A N 
  4*02401 175 N N 
  NC1*00201 1236 N/A N 
176 1*00901 194 N/A N 
  1*02301 45383 Y Y 
  1*03101 428 N/A N 
  2*00801 5064 Y N 
  2*01601 189 N N 
  3*00201 1017 N N 
  4*02401 15160 Y Y 
  NC1*00201 359 N/A Y 
  NC1*00501 318 N/A N 
177 1*00901 166 N/A N 
  2*00801 3948 Y N 
  2*01201 3178 Y N 
  2*01601 172 N N 
  3*00201 100952 N Y 
  3*01701 685 N N 
  3*02702 149 N/A N 
  4*02401 345 N N 
182 1*00901 258 N/A N 
  1*01901 138 Y Y 
  1*03101 121 N/A N 
  2*00801 5597 Y N 
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  2*01601 226 N N 
  3*00201 644 N N 
  3*01701 846 N N 
  3*02702 151 N/A N 
  4*02401 19615 Y Y 
  6*01402 117 N/A N 
  NC1*00201 268 N/A N 
183 1*02301 13759 Y Y 
  4*02401 5205 N Y 
184 1*03101 412 N/A N 
  2*00801 521 Y N 
  2*02601 3744 N/A N 
  2*03201N 153 N/A N 
  3*02702 3408 N/A Y 
  4*02401 115 N N 
185 1*00901 140 N/A N 
  1*03101 708 N/A N 
  2*00801 1019 Y N 
  2*01601 179 N N 
  2*02601 8028 N/A Y 
  2*03201N 359 N/A N 
  3*01701 650 N N 
  3*02702 7360 N/A Y 
  4*02401 256 N N 
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Major histocompatibility complex (MHC) class I molecules regulate adaptive 
immune responses through the presentation of antigenic peptides to CD8+ T-cells. 
Polymorphisms in the peptide binding region of class I molecules determine peptide 
binding affinity and stability during antigen presentation, and different antigen peptide 
motifs are associated with specific genetic sequences of class I molecules. Understanding 
bovine leukocyte antigen (BoLA), peptide-MHC class I binding specificities may 
facilitate development of vaccines or reagents for quantifying the adaptive immune 
response to intracellular pathogens, such as foot and mouth disease virus (FMDV). Six 
synthetic BoLA class I (BoLA-I) molecules were produced and the peptide binding motif 
was generated for five of the six molecules using a combined approach of positional 
scanning combinatorial peptide libraries (PSCPL) and neural network based predictions 
(NetMHCpan). The updated NetMHCpan server was used to predict BoLA-I binding 
peptides within the P1 structural polyprotein sequence of FMDV (strain A24 Cruzeiro) 
for BoLA-1*01901, -2*00801, -2*01201 and -4*02401. Peptide binding affinity and 
stability was determined for these BoLA-I molecules using the luminescent oxygen 
channeling immunoassay (LOCI) and scintillation proximity assay (SPA). The functional 
diversity of known BoLA alleles was predicted using the MHCcluster tool and functional 
predictions for peptide motifs were compared to observed data from this and prior 
studies. Results of these analyses showed that BoLA alleles cluster into three distinct 
groups with the potential to define ‘BoLA supertypes’. This streamlined approach 
identifies potential T-cell epitopes from pathogens, such as FMDV and provides insight 
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into T-cell immunity following infection or vaccination. 
Keywords: MHC class I, motif, peptide, FMDV, epitope, Immunoinformatics 
3.2. Introduction 
Peptide binding to major histocompatibility complex (MHC) class I molecules is 
the most selective step in determining immunogenicity and immunodominance of 
antigens from intracellular pathogens such as viruses (Yewdell and Bennink 1999). The 
alpha-one and alpha-two domains of MHC class I molecules form a binding cleft that 
presents short poly-peptides derived from cytosolic and nuclear proteins. Given the 
thousands of potential 8 to 11 amino acid poly-peptides that can be generated from the 
proteins of intracellular pathogens, antigenic peptides that stably bind to major 
histocompatibility complex (MHC) class I molecules are relatively rare. The peptides that 
bind to class I molecules often share common features (i.e., motifs); this is a function of 
key amino acid residues in the binding pockets of the MHC molecules. The antigenic 
peptides (epitopes) presented in the context of MHC class I molecules on the surface of 
virus-infected cells or activated antigen presenting dendritic cells are recognized by T-
cell receptors (TCRs) on CD8+ T lymphocytes. Upon recognition of the peptide-MHC 
class I complexes naïve CD8+ T-cells expand and differentiate into cytotoxic T 
lymphocytes (CTLs). These cells recognize and kill virus-infected cells through several 
mechanisms such as perforin, granzyme, and Fas ligand pathways (Groscurth and 
Filgueira 1998).  
MHC class I molecules can be characterized based on their ability to bind specific 
peptide motifs (Stryhn et al. 1996). MHC class I molecules preferentially bind peptides of 
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8 to 11 amino acids, most commonly with dominant anchor residues located at positions 
2 and 3 relative to the amino terminus, and at the C-terminus. Residues at other positions 
(e.g., positions 1, 4, 5, 6, 7, 8) may also influence peptide binding and affect TCR binding 
to the MHC-peptide complex (Calis et al. 2013; Frankild et al. 2008). For example, a 
large fraction of human leukocyte antigen (HLA) alleles are associated with specificities 
for proline in position two (P2) and hydrophobic residues at the C-terminus (B7-
supertype), or with hydrophobic residues in P2 and positive charges at the C-terminus 
(A3-supertype) (Sidney et al. 2008). Similar anchor residues are reported in other species 
such as cattle, pigs, birds, and chimpanzees (Follin et al. 2013; Hansen et al. 2014; 
Pedersen et al. 2012; Thomsen et al. 2013). Among cattle, there are currently 95 classical 
MHC class I alleles listed in the Immuno-Polymorphism Database (IPD-MHC; 
http://www.ebi.ac.uk/ipd/) although additional alleles have been reported (Hansen et al. 
2014). Peptide binding motifs or epitopes have been described for at least 13 bovine 
leukocyte antigen class I (BoLA-I) molecules (Bamford et al. 1995; De Groot et al. 2003; 
Gaddum et al. 1996a; Gaddum et al. 1996b; Graham et al. 2008; Guzman et al. 2010; 
Hansen et al. 2014; Hart et al. 2011; Hegde et al. 1999; Hegde et al. 1995; Hegde and 
Srikumaran 2000; Li et al. 2011; MacHugh et al. 2011; Momtaz et al. 2014; Nene et al. 
2012; Sinnathamby et al. 2004; Svitek et al. 2014). Two of these studies focused on 
predicting antigenic peptides of foot and mouth disease virus (FMDV) (Guzman et al. 
2010; Momtaz et al. 2014), while additional studies examined the induction of CTL 
response following FMDV infection or vaccination in cattle (Childerstone et al. 1999; 
Guzman et al. 2008) and swine (Patch et al. 2013; Patch et al. 2011). The potential role of 
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CD8+ T-cell responses in FMDV infections or following vaccination remains 
controversial, as most FMDV vaccination research has focused on the role of virus 
neutralizing antibodies (Grubman et al. 2010). Evidence of CD8+ T-cell responses from 
the few prior studies suggests additional research is justified, as understanding MHC 
class I FMDV epitopes and bovine CTL responses following infection or vaccination 
may identify opportunities to advance FMDV vaccine development.    
FMDV is a picornavirus of the Aphthovirus genus with a linear (non-segmented) 
genome of single-stranded positive-sense RNA approximately 8.2 kilobases in length 
(Grubman et al. 2010). The genome is translated as a single polyprotein, which is cleaved 
by the activity of viral proteases. The P1-2A precursor portion of full-length polyprotein 
includes four structural capsid proteins: VP4, VP2, VP3 and VP1. FMDV causes an acute 
highly contagious febrile disease with vesicular lesions in cloven-hoofed animals, 
including domestic cattle and swine. Infection negatively impacts milk and meat 
production, and outbreaks in naïve populations are characterized by rapid spread and 
significant morbidity. Vaccination is an important component of FMDV control in 
endemic countries and will be increasingly essential in response to any future outbreaks 
in countries or regions currently free of FMDV (Grubman et al. 2010). Adenovirus- 
vectored FMDV vaccine has recently received conditional approval for use in the United 
States. This vaccine construct contains nucleotide sequence encoding the FMDV P1-2A 
structural proteins and the 3C protease genes inserted into the E1 region of a replication 
incompetent adenovirus 5 (Ad5) vector (Brake et al. 2012; Grubman et al. 2010).  
Multiple species have benefited from the use of adenovirus as a vaccine vector, including 
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humans (human immunodeficiency virus), non-human primates (simian 
immunodeficiency virus), dogs (rabies), swine (porcine respiratory and reproductive 
syndrome virus) and cattle (bovine parainfluenza virus type 3, bovine herpes virus 1, and 
bovine viral diarrhea virus) (Tatsis and Ertl 2004). Human Ad5 vectors have been shown 
to specifically induce CD8+ T-cell responses in rodents, dogs, and nonhuman primates 
(Tatsis and Ertl 2004). 
The bioinformatics tools, such as NetMHCpan and NetMHC, can be used to 
predict peptides that are likely bound by the BoLA molecules, and to inform subsequent 
in vitro and ex vivo studies (Hansen et al. 2014; Nene et al. 2012; Svitek et al. 2014). 
These tools have been used to refine the peptide predictions obtained from previous 
studies (Nene et al. 2012), and have been applied to successfully identify immunogenic 
peptides of Theileria parva antigens driving CD8+ T-cell responses in cattle (Svitek et al. 
2014). The reverse immunology approach has been used in bacterial and viral pathogens, 
such as meningococcus B, human immunodeficiency virus, yellow fever virus, West Nile 
virus, dengue virus, herpes virus, and hepatitis C virus (Bruno et al. 2015; Rappuoli 
2001).  
In this study, we applied bioinformatic prediction tools, NetMHCpan-2.9 and 
MHCcluster, combined with high throughput biochemical affinity and stability assays to 
identify potential FMDV epitopes bound by MHC molecules expressed by Holstein cattle 
in the research and teaching herd at the University of Vermont (UVM). We were able to 
identify several in vitro binding peptides and characterized the peptide motifs for five out 
of six BoLA molecules. This research provides insight into specific viral derived peptides 
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that could induce bovine CD8+ T-cells after infection or vaccination. This approach is a 
rapid and accurate method to identify T-cell epitopes and sets the stage to examine T-cell 
specific immune responses in Holstein cattle, other domestic cattle breeds and perhaps 
other bovids.  
3.3. Materials and Methods 
3.3.1 Animals  
Whole blood samples (8-10 ml in K3-EDTA) were taken by jugular or caudal tail 
venipuncture from 81 purebred Holstein cattle from the UVM Dairy Center of Excellence 
(DCE) research herd. Blood samples were held on ice and within two hours of sampling 
peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation using Histopaque 1083 (Sigma-Aldrich, St. Louis, MO). All animal use 
procedures were conducted in accordance with protocol #13-059 approved by the UVM 
Institutional Animal Care and Use Committee.  
3.3.2 RNA extraction and cDNA synthesis 
RNA was purified from PBMCs using manufacturer’s instructions for TRIzol 
Reagent in combination with RNeasy mini kit (Qiagen, Valencia, CA). Following RNA 
extraction, complementary DNA was generated using the ImProm-II Reverse 
Transcription System (Promega, Madison, WI) following manufacturer’s 
recommendations. 
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3.3.3. BoLA typing by polymerase chain reaction with sequence-specific primers (PCR-
SSP) 
 PCR-SSP for a panel of 15 BoLA alleles was performed according to Ellis et al., 
(1998) with slight modifications.  Primers to amplify a 16th allele (BoLA-2*01201) were 
obtained from Codner (2010). PCR reaction mixtures consisted of 3.5 mM MgCl, 0.2 
mM dNTPs, 1 µM of each primer, and 1.25 units of Taq polymerase in 1X buffer (10 
mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl (New England Biolabs, Ipswich, MA)) in a 
final reaction volume of 50 µL. Previously published annealing temperatures were 
adjusted for primer pairs 1, 5, 6, 7, 8, 10, 11, 13, 15, and 16, using the formula Tm(°C)= 
[67.5 + 0.34(%GC X 100) - 395/length of the primer]. The cycling conditions were 95oC 
for 60 s followed by 30 PCR cycles of 95oC for 30 s, 55-61oC for 30 s, and 72oC for 30 s 
using a programmable C1000 Thermal Cycler (Bio-Rad, Hercules, California). Positive 
control cDNA for BoLA-3*00201, -1*02301, and -6*01301 was kindly provided by Dr. 
Ivan Morrison (Roslin Institute, University of Edinburgh, Edinburgh, Scotland). 
3.3.4 Positional Scanning Combinatorial Peptide Libraries and FMDV peptides  
Positional scanning combinatorial peptide library (PSCPL) peptides were 
synthesized using solid-phase Fmoc chemistry on 2-chlorotriyl chloride resins and 
purchased from Schafer-N Copenhagen, Denmark (www.schafer-n.com).  Briefly, an 
equimolar mixture of 19 of the common Fmoc amino acids (excluding cysteine) was 
prepared for each synthesis and used for coupling in eight positions, whereas a single 
Fmoc amino acid (including cysteine) was used in one position. This position was 
changed in each synthesis starting with the N-terminus and ending with the C-terminus. 
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In one synthesis, the amino acid (AA) pool was used in all nine positions. Therefore, the 
library consisted of 20 x 9 + 1 = 181 individual peptide libraries, and includes: 
• 20 PSCPL sublibraries describing position 1: AX8, CX8, DX8, ... YX8  
• 20 PSCPL sublibraries describing position 2: XA X7, XC X7, XD X7, ... XY X7 
• Etc.  
• 20 PSCPL sublibraries describing position 9: X8A, X8C,  X8D, ... X8Y  
• A completely random nonamer peptide library pool: X9,  
where, X denotes the random incorporation of AA from the mixture, and a single-letter 
AA abbreviation is used to denote the identity of a fixed AA (e.g., A, alanine). Following 
synthesis, the peptides were cleaved from the resin in trifluoroacetic acid/1,2- 
ethanedithiol/triisopropylsilane/water 95:2:1:3 v/v/v/v, precipitated in cold diethyl ether 
and extracted with water before desalting on C18-columns, freeze drying, and weighing.  
  Peptides for the predicted FMDV CD8+ T-cell epitopes were synthesized by 9-
fluorenylmethyloxycarbonyl (Fmoc) chemistry, purified by reverse-phase high-
performance liquid chromatography (to at least >90% purity), validated by mass 
spectrometry, and quantified by weight (GenScript, Piscataway, NJ). 
3.3.5 Synthesis of recombinant MHC-I heavy chain proteins 
Recombinant molecules BoLA-1*01901, -2*00801, -2*01601, -3*01701, -
4*02401, and -6*01302 were produced as previously described (Hansen et al. 2014). In 
brief, each BoLA molecule was generated in Escherichia coli including a biotinylation 
substrate peptide (BSP) at the N-terminal end, which was biotinylated in vivo using a co-
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induced BirA enzyme and the addition of biotin during the expression. E. coli were 
harvested as inclusion bodies, extracted into Tris buffered 8M urea and purified using ion 
exchange, hydrophobic, and gel filtration chromatography. MHC-I heavy chain proteins 
were never exposed to reducing conditions, which allows for purification of highly active 
pre-oxidized BoLA molecules when diluted into an appropriate reaction buffer. The pre-
oxidized, denatured proteins were stored at −20◦C in Tris buffered 8M urea. 
3.3.6 Production of MHC-I light chain (beta-2-microglobulin, β2m) protein 
Native, recombinant human and bovine β2m were expressed and purified as 
previously described (Hansen et al. 2014). Briefly, a histidine affinity tag (HAT) 
followed by an FXa restriction enzyme site was inserted N-terminally of a synthetic gene 
encoding the native, mature human or bovine β2m. The recombinant gene was expressed 
in the E. coli expression host, BL21 (DE3), harvested as inclusion bodies, extracted into a 
urea buffer, and purified. The tagged β2m protein was digested for 48 h at room 
temperature with the FXa protease releasing intact natively folded β2m. The folded β2m 
was purified as previously described, and fractions containing β2m were identified by 
A280 UV absorbance and SDS-PAGE, and then pooled. Protein concentrations were 
determined by BCA assay. The native β2m proteins were stored at −20◦C.  
3.3.7 Determining peptide-MHC-I binding motifs by a scintillation proximity assay (SPA)  
Nonameric peptide binding motifs were determined for BoLA-1*01901, -
2*00801, -3*01701, -4*02401, and -6*01302 using the PSCPL as previously described 
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(Hansen et al. 2014; Harndahl et al. 2011; Rasmussen et al. 2014). Recombinant, 
biotinylated MHC-I heavy chain molecules in 8M urea were diluted at least 100-fold into 
PBS buffer containing bovine β2m and peptide to initiate pMHC-I complex formation. 
The final concentration of MHC-I heavy chain was between 10-100 nM, depending on 
the specific activity of the MHC-I heavy chain. The reactions were carried out in the 
wells of streptavidin-coated scintillation 384-well Flashplate® PLUS microplates (Perkin 
Elmer, Waltham, MA). Recombinant bovine β2m was expressed, purified and 
radiolabeled with iodine (125I) as previously described (Harndahl et al. 2011).  125I-labeled 
β2m (approximately 1 nM, corresponding to approximately 25,000 cpm/well) and 
saturating concentrations (10 µM) of peptide were allowed to reach steady state by 
overnight incubation at 18°C. After overnight incubation excess unlabeled bovine β2m 
was added to a final concentration of 1 µM and the temperature was raised to 37°C to 
initiate dissociation. pMHC-I dissociation was monitored for 24 hours by consecutive 
measurement of the scintillation microplate on a scintillation TopCount NTX multiplate 
counter (Perkin Elmer, Waltham, MA). PSCPL dissociation data were analyzed as 
described (Rasmussen et al. 2014). Briefly, following background correction, the area 
under the dissociation curve (AUC) was calculated for each sub-library by summing the 
counts from 0-24 hours. The relative contribution of each residue in each position (i.e., 
the Relative Binding, RB) was calculated as RB=(AUCsublibrary/AUCX9). The RB values 
were normalized for each peptide position to give a sum of 20 for each residue. The 
anchor position (AP) value for each peptide position was calculated as:  
 77 
𝐴𝑃 = (1− 𝑅𝐵sublibrary)!!"!!!  
Data generated by the PSCPL assay for the five BoLA molecules were used to select a 
library of peptides to evaluate in vitro binding affinity of these molecules. 
3.3.8 Measuring peptide-MHC-I affinity interactions by luminescent oxygen channeling 
immunoassay (LOCI) AlphaScreenTM assay 
A set of up to 192 peptides was selected from our peptide repository, which 
contains over 9,000 nonamer peptides. Based on availability in the library, up to 96 high 
scoring peptides (rank score ≤ 0.5) according to the PSCPL matrices were selected, and 
as many as possible up to 96 additional peptides were selected based on NetMHCpan-2.8 
predictions, but with low affinity according to PSCPL. This combined method has been 
demonstrated to successfully identify high affinity MHC binding peptides, and inclusion 
of such data has been shown to improve the predictive performance of the NetMHCpan 
algorithm (Hansen et al. 2014; Hoof et al. 2009; Nielsen et al. 2008; Pedersen et al. 2012; 
Rasmussen et al. 2014).  
Affinity measurements of peptide-MHC-I interactions with MHC-I molecules 
were conducted using the AlphaScreenTM technology, as previously described (Harndahl 
et al. 2009). The donor and acceptor beads of the LOCI were purchased from Perkin 
Elmer (Waltham, MA). Donor beads were obtained pre-conjugated to streptavidin; 
acceptor beads were in-house conjugated to the monoclonal antibody W6/32 (gift from 
Dr. Jonathan Boyson), to a final concentration of 1 mg/ml using standard procedures as 
described by the manufacturer.  Recombinant, biotinylated MHC-I heavy chains, human 
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β2m and peptide were titrated in phosphate-buffered saline (PBS) with 0.1% Lutrol F-68 
as surfactant. They were allowed to fold for 48 hours at 18oC. The folding mixture was 
transferred to a 384-well Optiplate (Perkin Elmer, Waltham, MA). The donor and 
acceptor beads were each added to a final concentration of 5 µg/mL and incubated 
overnight at 18oC.  To ensure temperature equilibrium during the reading time, plates 
were placed at room temperature one hour prior to reading on BioTek Synergy H4 
(BioTek, Winooski, VT) or on an EnVision® multilabel reader (PerkinElmer, Waltham, 
MA). All handling of LOCI reagents was done in the dark or in green light.  
LOCI signals were converted to peptide-MHC-I complex concentration via a pre-
folded peptide-MHC-I complex standard. The peptide-MHC-I binding affinity was 
calculated by fitting peptide dose-response data to a one-site binding model 
(Y=Bmax*X/(Kd+X)) by non-linear regression where Y is the concentration of pMHC-I 
complexes formed and X is the concentration of ligand (i.e., peptide) (Harndahl et al. 
2009). The EC50 approximates the equilibrium dissociation constant (Kd) as long as the 
receptor concentration used is less than the Kd thus avoiding ligand depletion. Under 
conditions of limited receptor concentration ([MHC-I HC] ≤ Kd), the EC50 is a reasonable 
approximation of the Kd. Kd calculations were done in GraphPad Prism® 6 Software 
(GraphPad Software, Inc., San Diego, CA).  
3.3.9 Bioinformatics analysis of the FMDV peptide binding specificity of BoLA molecules 
The up-dated pan-specific algorithm NetMHCpan-2.9 (Hoof et al. 2009) was used 
to predict peptide-MHC-I interactions of BoLA-1*01901, -2*00801, -2*01201, and -
4*02401 with nonameric and decameric peptides of the P1 region of FMDV serotype 
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A24 Cruzeiro. The FMDV P1 sequence used in this analysis was obtained from Dr. 
Marvin Grubman (Personal Communication, Supplemental Fig. 1) and is the sequence 
used in construction of the new Adenoviral vectored FMDV vaccine (Brake et al. 2012).  
3.3.10 Measuring specific FMDV-peptide-MHC-I interactions by LOCI and SPA 
The top strong binding FMDV peptides, i.e., a NetMHCpan rank score of ≤0.5% 
were synthesized as described above for use in subsequent binding affinity (LOCI) and 
stability (SPA) assays with synthetic BoLA-1*01901, -2*00801, -2*01201, and -
4*02401. We also tested two weak binding peptides, i.e., those with a NetMHCpan rank 
score of 0.51-2%, thus, a total of 30 synthetic peptides were selected. Peptide-MHC 
stability in the dissociation SPA was expressed as a half-life in hours and, based on a 
previous study, we used a threshold of one hour to identify potential immunogenic 
epitopes (Harndahl et al., 2012). 
3.3.11 Functional predictions of BoLA molecules using MHCcluster, visualized with 
sequence logos 
MHCcluster server 2.1 was used to generate an unrooted tree and heat-map of the 
functional relationship between the BoLA molecules using full-length BoLA class I 
protein sequences, as previously described in Thomsen et al., (2013). Ovar-1-N*00201 
MHC-I sequence (GI:108792434) was also included. As part of the MHCcluster output, a 
sequence logo for each allele was generated using the Seq2Logo server (Thomsen and 
Nielsen 2012). The logos are visual representations of predicted nonamer amino acid 
binding motifs of individual BoLA molecules. Briefly, logos were created from the 
 80 
strongest binders (predicted top 1%) from a set of 100,000 random 9-mer peptides and 
were clustered using the Hobohm 1 algorithm with the similarity threshold of 63% to 
remove redundancy, and pseudo counts were applied with a weight on prior of 200 to 
account for a low number of observations. The accuracy of the predicted sequence motif 
is estimated from the distance to the “nearest neighbor” MHC molecule included in the 
training of the peptide binding prediction method; a value ≥ 0.70 is considered an 
accurate prediction and ≥ 0.90 is considered highly accurate (Hoof et al. 2009; Thomsen 
et al. 2013). 
3.4. Results 
3.4.1 BoLA class I typing of individual animals 
Frequency of known BoLA gene expression was determined by PCR-SSP (Ellis 
et al. 1998) for 81 Holstein cattle from the UVM teaching and research herd (Figure 3-1). 
We used the observed frequencies in our cattle population and availability of other 
recombinant BoLA molecules (e.g., BoLA-2*01201 (Hansen et al. 2014)) to inform 
synthesis of recombinant BoLA molecules for this study. We chose to synthesize BoLA-
1*01901, -2*00801, -2*01601, -3*01701, -4*02401, and -6*01302. 
3.4.2 Determining the peptide binding specificity of BoLA-1*01901, -2*00801, -3*01701, 
-4*02401, and -6*01302 by dissociation driven PSCPL analysis  
We applied a positional scanning combinatorial peptide libraries (PSCPLs) 
approach combining SPA based peptide-MHC-I dissociation assay with nonameric 
PSCPLs (Rasmussen et al. 2014) to analyze the peptide binding specificity of six BoLA-I 
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molecules: BoLA-1*01901, -2*00801, -2*01601, -3*01701, -4*02401, and -6*01302 
(Table 3-1). Peptide binding motifs (Figure 3-2) and PSCPL matrices (Figure 3-5) were 
derived for five BoLA MHC class I heavy chains, BoLA-1*01901, -2*00801, -3*01701, 
-4*02401, and -6*01302. Recombinant BoLA-2*01601 was also synthesized, but we 
were unable to derive a peptide binding motif for this molecule due to low signal-to-
background ratio in the SPA-based pMHC-I dissociation assay (data not shown). Overall, 
the shape of the motifs of these BoLA molecules appeared to be very similar to 
previously reported BoLA motifs with anchor positions at the N- and C-terminal parts of 
the peptide (Hansen et al. 2014). All molecules had prominent anchors in C terminal 
position 9 (P9) and a few motifs had a less defined primary anchor position at position 2 
(P2) or position 3 (P3). The BoLA-1*01901 molecule had a pronounced anchor position 
in P2, P3, and P9 with strong preference for glutamic acid in P2, preference for arginine 
or lysine in P3, and alanine, valine or serine in P9. BoLA-2*00801 and -4*02401 have 
very similar peptide binding motifs; both contain less pronounced anchors in P2, but had 
strongly pronounced preference for aromatic amino acids in the C-terminal (P9) peptide 
position (Figure 3-2). The motif for BoLA-3*01701 was rather unique with potential 
anchor residues in P2, P3, P5, P8 and P9. BoLA-3*01701 had a strong pronounced 
preference for glycine in P2, and preferences for amino acids with more neutral side 
chains in P3. BoLA-3*01701 also appeared to favor asparagine or methionine in P5, and 
asparagine, proline or valine in P8. Similar to BoLA-1*01901, BoLA-3*01701 strongly 
favored alanine and valine in P9. The motif for BoLA-6*01302 had a distinct preference 
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for hydrophobic amino acids, such as leucine, phenylalanine, isoleucine, and methionine 
in P9 and a less pronounced P2 anchor with preference for glutamic acid and glutamine. 
3.4.3 BoLA binding affinity for predicted nonameric peptides and retraining NetMHCpan 
for specific BoLA molecules 
Peptide-MHC-I affinity interactions were measure by LOCI and these data were 
used to update the existing bioinformatics predictor NetMHCpan v2.8. In this approach, 
the PSCPL matrices are used to select predicted BoLA-I binding peptides from an in-
house repository of >9,000 nonameric peptides. To complement this selection method, 
NetMHCpan v2.8 was used to select additional strong binding peptides from the 
repository that were not predicted to bind according to the PSCPL derived binding 
matrix. We have previously demonstrated that using either the PSCPL or the 
NetMHCpan method alone is suboptimal to improve the predictive algorithm (Hansen et 
al. 2014; Rasmussen et al. 2014). These previous studies concluded that PSCPL matrix 
guided selection will be able to identify a large proportion of binders, although in many 
cases this will not cover the complete binding space of a particular MHC molecule. The 
number of predicted binders available from the nonamer peptide repository included 170, 
170, 145, 170, and 157 peptides for BoLA-1*01901, -2*00801, -3*01701, -4*02401, and 
-6*01302 molecules, respectively (Table 3-2). For each BoLA molecule-peptide 
combination, the binding affinity was subsequently determined using the LOCI assay 
(Hansen et al. 2014; Harndahl et al. 2009). Binding affinity data was already available for 
BoLA-2*01201 (Hansen et al. 2014), the molecule found at the highest frequency in our 
herd. For BoLA-2*00801, and 6*01302 >90% of the peptides from the pool of PSCPL 
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matrix predicted peptides were found to bind with an affinity <500nM. Greater than 60% 
of the predicted peptides identified by the complementary NetMHCpan-2.8 prediction 
bound at the same affinity (Table 3-2). Similarly, the PSCPL matrix based prediction for 
BoLA-1*01901 and -4*02401, found 31% and 40% of the predicted peptides for each 
molecule to bind with an affinity <500nM. The NetMHCpan v2.8 prediction identified 
additional strong binding peptides (4 and 10% of peptides predicted by NetMHCpan v2.8 
were found to bind to BoLA-1*01901 and -4*02401, respectively, Table 3-2). The 
complementary method of PSCPL matrix plus NetMHCpan predictions identified a large 
number of MHC-I binding peptides that can in turn be used to update the prediction 
algorithm (Hansen et al. 2014; Rasmussen et al. 2014). One exception was BoLA-
3*01701 where only 4% of the peptides predicted to bind according to the PSCPL 
matrix-based-prediction bound with an affinity <500nM, and the NetMHCpan v2.8 
prediction identified no additional binders (Table 3-2). The small number of binders 
found for BoLA-3*01701 is potentially due to the bias in the peptide repository. The 
prevalence of peptides matching BoLA-3*01701 motif is much lower compared to the 
other molecules, and in particular there are no peptides in our repository that match both 
preferred anchor amino acids, glycine in P2, and alanine or valine in P9. Similar results 
have been seen for HLA-C*0401(Rasmussen et al. 2014).  
The data generated from the LOCI binding assay were used to retrain and update 
the NetMHCpan algorithm for the BoLA-1*01901, -2*00801, -2*01201, -4*02401 and -
6*01302. The estimated prediction accuracies in NetMHCpan-2.8 for these 5 molecules 
were 0.489, 0.437, 0.853, 0.398, and 0.809 respectively, and following retraining the 
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accuracies improved to 0.853 for each molecule in NetMHCpan v2.9. The accuracy 
predictions were extracted from MHCcluster output and were calculated from the 
distance to the nearest neighbor in the training data of NetMHCpan v2.9. 
3.4.4 Identification of peptides derived from FMDV and bound by BoLA-1*01901, -
2*00801, -2*01201, and -4*02401.  
The updated version of NetMHCpan v2.9 was used to make FMDV peptide 
predictions and is available at (http://www.cbs.dtu.dk/services/NetMHCpan/). The 736 
amino acid fragment of FMDV P1 capsid proteins (Figure 3-4) used in this study 
generates a total of 1455 peptides (728 nonameric and 727 decameric peptides). 
Screening of these potential epitopes using a NetMHCpan v2.9 rank score threshold of 
≤0.5% identified 28 FMDV candidate peptides binding to 4 BoLA molecules found 
frequently in our herd: 1*01901, 2*00801, 2*01201, and 4*02401 (Table 3-1 and Figure 
3-2). We also included 2 peptides with rank score of 0.51-2%. Although functional 
synthetic molecules are available for BoLA-6*01302, our goal was to focus on molecules 
most frequently observed in our herd and FMDV peptide binding assays was not 
performed for -6*01302 at this time.  
Among the 30 peptides, 25 (13 nonamers, and 12 decamers), were predicted to 
bind with strong or weak affinity to a single BoLA molecule, while five peptides 
240MTAHITVPY248, 444AAHCIHAEW452, 207LLVAMVPEW215, 443RAAHCIHAEW452, 
604VVRHEGNLTW613 were common to more than one BoLA molecule. 5 nonamer 
peptides were nested within decamer peptides that were predicted to bind the same 
molecule. Only two 10-mer peptides were predicted to be strong binders (rank score ≤ 
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0.5) to BoLA-1*01901 allele, while thirteen peptides were predicted to bind to BoLA-
2*00801 (six 9-mers, and seven 10-mers) and nine peptides were predicted as strong 
binders to BoLA-2*01201 (six 9-mers, and three 10-mers).  Two peptides, 
386AAKHMSNTY394 and 240MTAHITVPY248, were predicted to be weak binders (rank 
score > 0.5) to BoLA-2*00801 and BoLA-2*01201, respectively.  
The 30 peptides were tested for in vitro binding affinity and stability using the 
LOCI and SPA assays (Table 3-1). In this study, we included 2 peptides 
(386AAKHMSNTY394 and 240MTAHITVPY248), which were predicted by NetMHCpan to 
be weak binders; these peptides were found to be either weak- or non-binding in the 
LOCI assay and had short binding half-lives (≤ 0.3 hrs.) in the SPA. In comparison, 
among the 28 peptides predicted to be strong binders by netMHCpan v2.9, the LOCI 
assay identified 9 strong (Kd < 50 nM), 5 intermediate (Kd = 50 – 499 nM) and 10 weak 
(Kd = 500-5000 nM) binders (Table 3-1), and 13 molecules had binding stabilities > 1 
hour in the SPA. LOCI binding affinity thresholds suggest at least one weak binder (Kd ≤ 
5,000 nM) was identified for each BoLA molecule. Only two molecules, BoLA-2*00801 
and -2*01201, had peptides that were predicted strong or intermediate binders, whereas 
only weak binding or non-binding peptides were found for BoLA-1*01901 and 4*02401. 
We identified 9 strong binders (Kd < 50nM) for BoLA-2*00801.  A SPA binding 
stability half-life greater than 1 hour was identified for 7, 4, and 2 peptides for BoLA-
2*00801, -2*01201, and -4*02401 molecules, respectively, suggesting there may be 
immunogenic peptides among the predictions for these 3 molecules.  
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3.4.5 Functional predictions of BoLA class I allele groups 
The MHCcluster tree was generated to predict the functional relationship of the 
BoLA molecules. Three large clusters were found (Figure 3-3). Structural motifs and 
binding specificities were predicted for all BoLA molecules. Logos highlighting the 
binding specificity are shown for a subset of 15 BoLA molecules (highlighted in red in 
Figure 3-3). Molecules predicted to have similar binding specificity clustered closely 
together. For example, BoLA-2*00801 and -4*02401 shared a favored binding specificity 
for aromatic amino acids, tryptophan, phenylalanine and tyrosine in the C-terminal 
peptide position. A static heat-map describing the functional relationship of the BoLA 
molecules is shown in figure 3-6.    
3.5. Discussion 
We have extended our approach for epitope discovery, including 
immunoinformatics and biochemical peptide binding affinity and stability assays, to 
identify candidate FMDV class I MHC restricted epitopes in Holstein cattle. Previous 
work using this approach has focused on epitope prediction for T. parva antigens (Hansen 
et al. 2014; Nene et al. 2012; Svitek et al. 2014). Three observations have emerged from 
these prior studies. First, peptides that have been previously identified as epitopes from 
experimental studies are frequently identified as potential epitopes by the NetMHCpan 
predictor. Second, the predictor will often identify alternative peptides that are predicted 
to have higher binding affinity compared to CD8+ T-cell epitopes previously identified in 
experimental studies, and these alternatives are frequently shorter peptides nested within 
the previously identified CD8+ T-cell epitope (Nene et al. 2012). Third, the process of 
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using epitope predictions to guide in vitro and ex vivo experiments generates new and 
sometimes unanticipated data that can be used to iteratively inform improvements in the 
NetMHCpan and subsequent live animal immune response studies.  
Only a fraction of peptides that bind to MHC molecules are CD8+ T-cell 
epitopes, with potential epitopes first narrowed by MHC class I determinants and further 
by TCR repertoire restriction and antigen processing (Yewdell and Bennink 1999). In 
order to be considered a CD8+ T-cell epitope, the pMHC complex must trigger a specific 
T-cell immune response. Peptide affinity and stability are two factors that play an 
important role in determining the immunogenicity of a peptide (Busch and Pamer 1998; 
Harndahl et al. 2012). Positional scanning combinatorial peptide libraries (PSCPLs) have 
successfully been applied to address peptide-MHC-I specificity of humans (Rasmussen et 
al. 2014; Stryhn et al. 1996), swine (Pedersen et al. 2012), and cattle (Hansen et al. 2014). 
In cattle epitopes or peptide binding motifs have been characterized for at least 13 BoLA 
molecules (Gaddum et al. 1996a; Gaddum et al. 1996b; Graham et al. 2007; Graham et 
al. 2008; Hansen et al. 2014; Hegde et al. 1999; Hegde et al. 1995; Li Pira et al. 2010; 
Macdonald et al. 2010; MacHugh et al. 2011; Momtaz et al. 2014; Nene et al. 2012; 
Svitek et al. 2014), and we have expanded characterization of peptide binding motifs for 
five additional molecules. We also produced recombinant BoLA-2*01601, but this 
molecule had a poor β2m complex-specific signal in the SPA using the PSCPL and 
predicted FMDV specific peptides were not tested in the LOCI or SPA assays. Possible 
reasons for this non-functional molecule could be poor quality of the protein preparation 
or intrinsic biochemical properties of the molecule that result in incompatibility with the 
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assay. For example, it is possible this particular molecule has a preference for 8-mers, 10-
mers or 11-mers instead of 9-mers used in the PSCPL, which would explain why a motif 
could not be derived (Stevens et al. 1998). Alternative approaches, such as peptide 
elution experiments, might be considered for molecules that appear to be incompatible 
with in vitro binding assays. While we were able to generate data for BoLA-3*01701 
using the PSCPL, subsequent testing in the SPA was unsuccessful, possibly due to loss of 
protein function, and specific FMDV peptide binding data was not generated in the LOCI 
or SPA. Another potential reason for the difficulty in characterizing the peptide binding 
affinity of BoLA-3*01701 could be due to a relatively limited peptide binding repertoire 
outside of the PSCPL. Further work to identify peptide motifs and epitopes for these two 
molecules is warranted as both appear to occupy regions of the MHCcluster diagram that 
lack in vivo or in vitro data supporting motif predictions (Figure 3-3). For example, 
BoLA-3*01701 estimated prediction accuracy is 0.47 using nearest neighbor Rhesus 
macaque Mamu-B3901 and this molecule has been previously described as potentially 
not conforming to more commonly found peptide motifs (De Groot et al. 2003). Again, 
peptide elution experiments might be the most effective method to characterize the 
peptide motif for BoLA-3*01701. In comparison, for BoLA-6*01301 where in vitro and 
in vivo data are available from eight different studies (Gaddum et al. 1996b; Graham et 
al. 2006; Graham et al. 2008; Guzman et al. 2008; Hansen et al. 2014; Macdonald et al. 
2010; Nene et al. 2012; Svitek et al. 2014), the estimated prediction accuracy is 0.853. 
While we did not identify BoLA-6*01301 in our herd, we did identify BoLA-6*01302 in 
25% of UVM-DCE Holstein cattle (Figure 3-1). A higher frequency of 6*01302 relative 
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to 6*01301 has also recently been reported in other cattle populations (Svitek et al., 
2015). A PSCPL matrix was derived for 6*01302; however, at this time we elected to 
complete in vitro binding assays for the four other molecules more frequently identified 
in our herd.   BoLA-2*01201 was previously synthesized and a motif was generated 
(Hansen et al. 2014), and we decided to test FMDV predicted peptides for this molecule 
because it was found in relatively high frequency in our herd. 
NetMHCpan-2.9 predicted 28 peptides derived from the FMDV structural 
proteins that would most likely bind four common BoLA molecules (BoLA-1*01901, -
2*00801, -2*01201, and -4*02401) identified among animals from our research herd. 
NetMHCpan is trained on human, mice, swine, and a handful of BoLA peptide-MHC 
binding data. It is capable of making accurate predictions where no binding data are 
available (Nielsen et al. 2008). In our current study, 50% (14/28) of the peptides 
predicted by the NetMHCpan-2.9 algorithm with a rank score ≤0.5% were demonstrated 
to have high or intermediate binding affinity in the LOCI assay. The number of predicted 
peptide binders for a particular molecule is affected by the rank cut-off value selected. 
For example, the algorithm predicted only two strong binding peptides for BoLA-
1*01901, and by increasing the rank threshold cutoff to greater than 2%, we could 
potentially identify more binders. However, previous benchmark studies determined the 
vast majority of epitopes have binding with a rank score of 2% or less (Erup Larsen et al. 
2011). Therefore, applying a NetMHCpan threshold of 2% allowed us to reduce the 
number of FMDV capsid protein 9- and 10-mer peptides from over 700 to 10 and 14 for 
alleles BoLA-2*01201 and -2*00801, respectively. Results of the binding assays allow us 
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to further narrow the pool of peptides that might be evaluated as potential epitopes in T 
cell response assays for vaccinated or virus challenged cattle, especially cattle expressing 
BoLA-2*00801 where we observed 7 peptides with binding stability half-lives > 1 hour. 
The limited number of potential epitopes identified for the remaining molecules could 
either be a function of a limited number of epitopes in FMDV structural proteins or 
current limitations in the predictive models.  
BoLA-2*00801 and -4*02401 share 92% sequence identity in the peptide binding 
groove, and were predicted to have similar peptide binding specificities. The algorithm 
predicted four FMDV peptides (444AAHCIHAEW452, 207LLVAMVPEW215, 
443RAAHCIHAEW452, 604VVRHEGNLTW613) as potential binders to both BoLA-
2*00801 and -4*02401. However, our in vitro results indicate that these peptides had 
strong affinity for BoLA-2*00801 and weak affinity for BoLA-4*02401. A potential 
reason for the differences in binding could be due to the subtle differences in the key 
amino acids in the anchor positions. Both molecules have common amino acids, 
tryptophan and phenylalanine in P9, however, the P2 anchor appears less important for 
BoLA-4*02401. The amino acids in P2 for BoLA-4*02401 have aromatic hydrophobic 
side chains, as opposed to BoLA-2*00801, which has amino acids with polar, neutral side 
chains in this position (Figure 3-2). This subtle difference could be the reason for weak 
binding by BoLA-4*02401. As more BoLA binding data are generated, the algorithm can 
be iteratively retrained to capture these differences.  
Perhaps more importantly, these data can be used to inform ex vivo CTL response 
or CD8+ tetramer assays using cells from cattle expressing these BoLA molecules. For 
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example, Svitek et al., (2014) recently used tetramer assays to identified a T. parva 
epitope (Tp587-95) that binds to two BoLA molecules (-1*02301 and -T5). The role of 
cattle CD8+ T-cell responses to FMDV infection or vaccination remains controversial 
and a limited number of studies have evaluated class I restricted CD8+ T-cell responses 
following FMDV infection or vaccination (Childerstone et al. 1999; Guzman et al. 2010; 
Guzman et al. 2008; Patch et al. 2013; Patch et al. 2011). An important next step is to test 
whether the peptides identified in this study are MHC-I epitopes in cattle expressing the 
BoLA molecules evaluated in this study. For example, the CD8+ response to peptides 
identified in this study could be evaluated among cattle vaccinated with the AD5-FMDV 
vaccine expressing A24 P1 capsid proteins.  
Thus far, it appears that leucine, phenylalanine, isoleucine, and methionine are 
important anchor residues in P9 of the BoLA class I binding motif. Position two is more 
variable, with glutamic acid, glutamine, leucine, arginine, threonine, and serine being the 
most commonly favored amino acids in this anchor position. In one specific cluster, 
tryptophan was identified as a strong anchor residue in P9. In another cluster, lysine and 
arginine were identified as favored anchor residues in P9. Some motif predictions have 
been validated in animals. For example, the CD8+ T-cell antigen Tp2 and epitope 
49KSSHGMGKVGK59 from the Muguga strain of T. parva, matched the binding 
specificity for BoLA-2*01201 predicted by the algorithms (Nene et al. 2012). In contrast, 
MHC cluster did not capture the P5 anchor of the BoLA-6*01301 molecule previously 
identified to bind an immunogenic peptide (Macdonald et al. 2010). This is not surprising 
as the P5 anchor appears to be relatively rare and these rare events are less well 
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recognized by the predictor tool. We also find it worth noting that peptides without the P5 
anchor appear to have strong binding affinities for BoLA-6*01301 and -6*01302 and 
these peptides are immunogenic (Hansen et al. 2014; Svitek et al. 2015).   
The functional relationship between all known BoLA molecules was predicted 
using the MHCcluster algorithm. The characterization of the BoLA binding specificities 
may also make it possible to cluster molecules that share largely overlapping peptide 
binding specificities (i.e., BoLA supertypes) (Lund et al. 2004; Sidney et al. 2008). A 
MHC cluster tree generated following inclusion of our data shows there are currently two 
clusters lacking binding data; representative molecules from each of these clusters are 
highlighted in blue (Figure 3-3). The predictions of the NetMHCpan v2.9 and 
MHCcluster algorithms can be improved by characterizing the binding specificity of 
additional BoLA molecules, perhaps by first addressing regions of the tree currently 
lacking coverage.  
In conclusion, we have translated technologies that have been applied to the study 
of human T-cell responses to the study of cattle immunity. These technologies include 
bioinformatics, peptide synthesis, and proteomics. Using FMDV or other important 
pathogens, extending this research should advance our understanding of how viral 
antigens are recognized by the bovine immune system, and contribute to improved 
vaccine development against bovine pathogens.  
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Figure 3-1: Frequency of BoLA class I alleles in 81 Holstein cattle from the UVM Dairy Center of 





















































































Table 3-1: FMDV (strain A24) P1 region peptides predicted as strong (n=28) or weak (n=2) binders 








Table 1. 30 peptides predicted as strong or weak binders using NetMHCpan v2.9 from the P1 region of FMDV strain A24 
BoLA molecule Peptide Sequencea NetMHCpan Predicted % rank scoreb kD (nM) Actual binding statusc
1*01901 200NQFNGGCLLV209 0.5 1086 Weak
499AENDTLVVSV508 0.12 7817 Non-binder
2*00801 60TTNTQNNDW68 0.4 9 Strong
653TVYNGTSKY661 0.4 5 Strong
114SSVGVTHGY122 0.15 6 Strong
444AAHCIHAEW452 0.25 21 Strong
207LLVAMVPEW215 0.3 2 Strong
443RAAHCIHAEW452 0.08 1.7 Strong
604VVRHEGNLTW613 0.15 11 Strong
59HTTNTQNNDW68 0.3 40 Strong
182DSYAYMRNGW191 0.25 2 Strong 
240MTAHITVPY248 0.25 51 Intermediate
332KVYNPPRTNY341 0.5 393 Intermediate
386AAKHMSNTY394 1.5 1299 Weak
385LAAKHMSNTY394 0.5 1380 Weak
284KVYANIAPTY293 0.4 >10,000 Non-binder
2*01201 685ASFNYGAIK693 0.01 67 Intermediate
626TSNPTAYNK634 0.25 226 Intermediate
324KTADPAYGK332 0.25 443 Intermediate
490CIYQITHGK498 0.5 1035 Weak
371RTDDTRLLAK380 0.4 4176 Weak
140RVVQAERFYK149 0.4 1353 Weak
141VVQAERFYK149 0.25 >20,000 Non-binder
250GVNRYDQYK258 0.5 8693 Non-binder
240MTAHITVPY248 1.5 5547 Non-binder
630TAYNKAPFTR639 0.4 >20,000 Non-binder
4*02401 444AAHCIHAEW452 0.2 572 Weak
207LLVAMVPEW215 0.15 588 Weak
443RAAHCIHAEW452 0.08 1792 Weak
604VVRHEGNLTW613 0.4 1001 Weak
aPeptide positions are relative to the peptide sequence shown in supplemental figure 2
b9mer or 10mer peptides predicted as strong binders (rank score < 0.5) or weak binders (rank score > 0.5) using NetMHCpan v2.9
cActual binding status according to the LOCI assay. Strong binder (Kd <50nM), intermediate binder (Kd 50-500nM), weak binder (Kd 501-5000nM), non-binder (Kd >5000nM) 



































Figure 3-2: Sequence logo representations of BoLA-1*01901, 2*00801, 4*02401, 6*01302 binding 
motifs. The logo for BoLA-2*01201 has been previously described (Hansen et al. 2014). The logos 
were calculated from the top 1% highest scoring peptides selected from a pool of 9-mer peptides 
using the positional scanning combinatorial peptide library matrix. In the sequence logo, each 
peptide position is represented by a stack of letters indicating its significance for binding and the 
height of each amino acid is proportional to its relative frequency (Thomsen and Nielsen 2012). 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3-3: A tree representing the functional clustering of BoLA molecules using the MHCcluster 
method. The tree was visualized using the tree viewer of MHCcluster. Predicted motifs for these 
clusters are highlighted with a representative BoLA molecule in red. The two main clusters where 
BoLA molecules and their binding affinity and specificity have not been characterized are shown 

















































Figure 3-5: PSCPL Matrices of BoLA-1*01901, -2*00801, -3*01701, -4*02401 and -6*01302 
determined by SPA. Relative binding values >2 are considered favored amino acids, values 0.5-1.5 
are considered tolerated and values below 0.5 are considered disfavored. AP values > 10 are 
considered anchor positions. The sequence logos were generated using the Seq2Logo server 




Figure 3-6: Static heat-map representation of MHC cluster tree showing the degree of functional 
relationship between BoLA molecules in Figure 3. Red color indicates closer functional relationship, 












































































































































































































































































































































































































































































































































































































































































































































































































Table 3-2: Distribution of peptide-BoLA-I binding affinity for peptides predicted to bind 
according to either PSPCL matrix based prediction or NetMHCpan prediction (of peptides 
with low-scoring PSCPL matrix values). 
 110 
 
4. CHAPTER 4: INDUCTION OF A CD8+ T CELL RESPONSE WITH 
ADENOVIRAL VECTOR BASED FMDV VACCINE ENCODING P1 
LINKED TO THE MHC CLASS II CHAPERONE PROTEIN INVARIANT 
CHAIN 
This manuscript has been formatted for Veterinary Research.  
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Foot and mouth disease (FMD) is a highly infectious and economically 
devastating viral disease of livestock. Recent vaccination strategies are directed primarily 
toward the induction of neutralizing antibody responses. Current FMD virus (FMDV) 
vaccines have yielded partial successes, eradicating disease in some areas of the world 
and delaying disease in others. However, several challenges of vaccine design still remain 
such as short duration of immunity and serotype-specific protection. The primary goal of 
this study was to improve vaccine performance by targeting cellular immunity. Here, we 
have used a recombinant human adenovirus vector to deliver the P1 capsid of FMDV 
tethered to the bovine major histocompatibility complex (cattle MHC; BoLA) class II 
chaperone protein invariant chain (Ii) to investigate the CD8+ T cell responses in cattle. 
The vaccine construct induced a CD8+ T cell response that was measured by IFN-γ 
release. This response was directed towards two epitopes, 653TVYNGTSKY215 and 
207LLVAMVPEW215, within the P1 capsid proteins of FMDV strain A24. In an attempt to 
show MHC class I restriction peptide-MHC tetramers were generated; however, no 
tetramer specific staining of T cells was detected. Our results show that identification of 
these epitopes is important in not only the analysis of the cellular immune responses, but 




Keywords: IFN-γ ELIspot; Tetramers; Major Histocompatibility Complex class I; Cattle; 
Adenovirus 
4.2. Introduction 
Foot-and-mouth disease (FMD) is an economically and agriculturally important 
disease of cattle and other cloven-hoofed animals and is enzootic to all continents except 
Australia and North America [1, 2]. The highly infectious nature of the virus requires 
strict control measures to ensure reduced and restricted disease transmission. Current 
control strategies include vaccinating animals with chemically inactivated whole-virus in 
adjuvant vaccines, mass culling (stamping out) of susceptible animals in outbreaks and 
restrictions on the exportation of contaminated animals or animal products. Both 
stamping out and trade restrictions can have devastating economic effects, as seen in the 
2001 UK outbreak which resulted in in the culling of over 4 million animals and a loss of 
$12-13.8 billion dollars [3, 4]. Outbreaks such as this highlight the need for better 
prevention, biosecurity and control measures, including improved vaccines. 
 FMD inactivated antigen vaccines have been in existence for more than 70 
years, these vaccines, though partially effective, have several limitations. First, the 
current FMDV killed virus vaccines achieve serotype and subtype specific protection in 
1-2 weeks, but fail to induce long-term protective immunity, thus revaccination is often 
required every 4 to 6 months [5, 6]. Production and manufacture of inactivated antigen 
vaccines requires growth of large quantities of virus in biosafety level 3 (specialized 
containment) facilities, virus inactivation and purification [7, 8]. Vaccines usually have a 
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short shelf life and cold-chain requirements [5]. Additionally, to differentiate infected 
from vaccinated animals (DIVA), vaccine production requires the removal of cellular 
contaminants as well as nonstructural viral proteins in order to support DIVA, this is 
essential for maintaining trade status [5]. 
Such vaccine challenges can be addressed by gaining a better understanding of the 
overall immune response to FMDV vaccination and infection. Generally, vaccination and 
infection induces a humoral response, generating serotype specific neutralizing antibodies 
which protect animals from clinical disease caused by homologous virus [1]. The virus 
has seven serotypes (A, O, C, Asia 1, and South African Territories 1, 2 and 3) and 
multiple subtypes occur within each serotype [1]. This is a problem for vaccine design, as 
the vaccine strain needs to match the circulating strain of the virus. FMDV infection is 
not always controlled solely with neutralizing antibodies, therefore other immune cells 
such as CD8+ T cells could have an important role in FMDV vaccine design and 
protection.  
CD8+ T cells are involved in controlling viral infections and recognize antigens 
presented by the major histocompatibility complex (MHC) class I molecules (Citation). 
Upon antigen recognition naïve CD8+ T cells differentiate into effector T cells, which 
recognize and kill infected cells thru two pathways such as direct cytotoxicity or release 
of cytokines such as IFN-γ (Citation). Several studies have explored the role of T cell 
mediated immune responses to FMDV in cattle and swine following infection or 
vaccination [9-19]. A few of these studies have demonstrated CD8+ T cell MHC class I 
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restriction in cattle and swine in FMDV [12, 13, 15, 17-19]. Despite these studies, the 
significance of the CD8+ T cells in protection and vaccination remain unclear.  
Over the past decade improvements in vaccine technology have helped address 
several FMD vaccine limitations. One such example was the development of an FMDV 
vaccine that is delivered by a replication defective human adenovirus serotype 5 vector 
(Ad5-FMD) [20]. Unlike the traditional killed virus vaccines, Ad5-FMD vaccine does not 
require large amounts of virus for production, is DIVA compatible and is protective in 
both cattle and swine [20]. However, similar to the traditional killed virus vaccines, 
neutralizing antibodies generated to the Ad5-FMD vaccine strain are serotype specific 
and do not provide protection across serotypes, or subtypes within serotypes [5].   
Recently, Patch et al., developed a recombinant human Ad5-FMD vectored 
vaccine containing a mutation in the 3Cprotease (3Cpro) to illicit a T cell directed immune 
response in swine [15]. They hypothesized this vaccine enhanced cytolytic activity by 
preventing 3Cpro from cleaving the capsid proteins, thus targeting all the FMDV proteins 
for degradation and increasing antigen presentation on MHC class I. It was demonstrated 
that in the absence of significant humoral immunity, a cytotoxic T cell (CTL) response 
could reduce clinical disease and decrease viremia in swine challenged with live virus 
[14]. Therefore, the combination of humoral and cellular immunity may be able to 
diminish outbreaks of FMDV especially when the infecting viruses are poorly matched to 
the serotype-specific vaccine strains available.  
 Previous studies in mice with an adenoviral vaccine vector system which 
expressed the glycoprotein of lymphocytic choriomeningitis virus tethered to the MHC 
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class II invariant chain (Ii), showed an enhanced immunogeneticity to CD4+ and CD8+ T 
cells [21-26]. In this proof of concept study, we have expanded upon these previous 
findings from bovine, swine and mice to study the CD8+ T cell response in cattle. We 
have designed a recombinant human Ad5 vector containing the P1 capsid of FMDV 
tethered to the bovine leukocyte antigen (Cattle MHC; BoLA) class II invariant chain 
lacking the 3Cpro, which we designate as Ad5-P1-Ii. Our hypothesis was that an 
intradermal vaccination with the Ad5-P1-Ii will generate a FMDV specific CD8+ T cell 
response by targeting proteins for degradation and presentation on MHC class I that can 
be measured by tetramer staining and IFN-γ release. Here we report after vaccination 
with Ad5-P1-Ii, two FMDV epitopes 653TVYNGTSKY215 and 207LLVAMVPEW215 
elicited an IFN-γ response by CD8+ T cells.  
4.3. Materials and Methods 
4.3.1. Animals 
Four Holstein steers (176, 182, 184, 185) 4-6 months old and weighing 300-500 
lbs were housed at the Miller research farm at the University of Vermont Dairy Center of 
Excellence (UVM-DCE). Animals were maintained according to UVM-DCE established 
practice. All animal procedures were reviewed and approved by University of Vermont 
Institutional Animal Care and Use Committee (protocol #13-059).  
4.3.2. Cell lines  
Human 293 cells (ATCC CRL-1573) were used to generate, grow and titer all 
recombinant human Ad5 vectors used in this study. Cells were maintained in MEM (Life 
 116 
Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone, Logan, UT), 1% L-glutamine (Life Technologies, Grand Island, NY), and 1% 
Penicillin-Streptomycin (Life Technologies, Grand Island, NY) Peripheral blood 
mononuclear cells (PBMCs) and CD8 T cells used in the ELISPOT assay were 
maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Life 
Technologies, Grand Island, NY) supplemented with 10% FBS (Hyclone, Logan, UT), 
1% L-glutamine (Life Technologies, Grand Island, NY), 1% Penicillin-Streptomycin 
(Life Technologies, Grand Island, NY) and 0.1% 2-mercaptoethanol (Life Technologies, 
Grand Island, NY). Swine kidney cells (IBRS2) were used in Western blot and 
maintained in DMEM supplemented with 10% FBS (Hyclone, Logan, UT), 1% L-
glutamine, 1% nonessential amino acids (Life Technologies, Grand Island, NY) and 1% 
Penicillin-Streptomycin (Life Technologies, Grand Island, NY). Baby hamster kidney 
(BHK-21) cells (ATCC CCL-10) were used in Western blot and maintained in basal 
medium Eagle (BME) (Life Technologies, Grand Island, NY) supplemented with 10% 
FBS, 10% tryptose phosphate broth (Life Technologies, Grand Island, NY), 1% L-
glutamine (Life Technologies, Grand Island, NY), and 1% Penicillin-Streptomycin (Life 
Technologies, Grand Island, NY).  
4.3.3. Vaccination  
Three Holstein steers (176, 184 and 185) were vaccinated with 3x109 PFU Ad5-
P1-Ii in PBS. PBS was administered to one additional Holstein steer (182) as a negative 
control. Animals were boosted with 1.25x109 PFU Ad5-P1-Ii in PBS. Initial dose of virus 
was delivered intradermally in a total of 3 ml to three sites on the neck (1.0 ml/site) using 
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a pulse injection system (Pulse NeedleFree systems, Lenexa, KS). For the boost, virus 
was delivered intradermally in a total of 5 ml to five sites on the neck (1.0 ml/site) using 
the pulse injection system (Pulse NeedleFree systems, Lenexa, KS).   
4.3.4. Isolation of PBMCs and CD8 T cells 
Whole blood and serum were collected from all four steers by jugular or caudal 
tail venipuncture into sodium heparin and serum vacutainer tubes (BD Biosciences, San 
Jose, CA) on days 0, 7, 14, 21 and 28 days post vaccination. Eleven weeks following 
initial vaccination, steers were boosted and samples were collected on days 0, 4, 7, 11, 
14, 21 and 28 post boost. 0.03mg/kg of xylazine (Lloyd Lab, Decatur, IL) was 
administered intravenously at all time points where whole blood was collected. PBMCs 
were isolated using Uni-Sep Maxi tubes (Novamed, Jerusalem, Israel). Briefly, 14 ml of 
whole blood was aliquoted into each Uni-Sep tube, and then centrifuged at 1000g for 20 
min at room temperature. The band of PBMCs was harvested and washed three times 
with 1xPBS (Life Technologies, Grand Island, NY), followed by suspension in complete 
RPMI. To positively select CD8+ T cells, purified PBMCs were labeled with monoclonal 
mouse anti-bovine CD8 ILA-105 (3µg/ml) followed by secondary goat anti-mouse 
IgG2a-PE (at 4µg/ml) (ThermoFisher Scientific, Suwanee, GA). Followed by MACS 
goat anti-mouse PE microbeads and separated on LS columns using a MidiMACS 
magnetic separator (Miltenyi Biotec, Gladbach, Germany), according to the 
manufacturer’s instructions.  
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4.3.5. Virus production 
The bovine invariant chain sequence (accession: NM_001034735.1) was used to 
design a fusion of invariant chain with the P1 region of FMDV strain A24, with invariant 
chain at the N-terminus. 4 µg of DNA containing the FMDV-P1-Ii was synthesized by 
Bio-Basic (Bio-Basic Inc, Amherst, NY). 100 µl of ddH20 was used to dissolve the DNA. 
Transformation was done using chemically competent E. coli cells as described 
previously [27]. Briefly, 2 µl of FMDV-P1-Ii DNA was added into a vial of E. coli cells, 
gently mixed, and incubated on ice for 30 minutes. Cells were then heat-shocked for 30 
seconds at 42°C and immediately transferred to ice. 250 µl of room temperature SOC 
medium was added to the cells, after which they were shaken horizontally (200 rpm) at 
37°C for 1 hour. The mixture was plated on Luria-Bertani (LB) plates (Teknova, 
Hollister, CA) containing 50 µg/ml of Ampicillin and incubated overnight at 37°C. Five 
colonies were picked and inoculated into 5 mls of LB broth containing 50 µg/ml of 
ampicillin and maintained overnight in a shaking incubator at 37°C.   
Plasmid DNA was isolated using PureLink™Quick Plasmid Miniprep Kit (Life 
Technologies, Grand Island, NY). The plasmid DNA underwent a restriction digest using 
ClaI and XbaI, and the product was run on 1% agarose gel to visualize the insert (2851 
bp). The band of interest was excised from the gel and purified using Qiaquick® gel 
purification kit (Qiagen, Valencia, CA). Plasmid Ad5-Blue was obtained from Dr. 
Marvin Grubman (Agricultural Research Service, USDA). The purified construct was 
ligated into the pAd5-Blue vector that had been digested with ClaI and XbaI, as 
previously described [27]. The final plasmid was linearized with PacI and 4 µg of DNA 
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was transfected into Human Embryonic Kidney (HEK) 293 cells (seeded two days prior 
to transfection) using Lipofectamine 2000 (Life Technologies, Grand Island, NY) at an 
insert to vector ratio of 3:1. The recombinant virus was harvested 4 days post 
transfection.  
Virus was extracted from the HEK293 cells by three consecutive freeze/thaw 
cycles and amplified by infection of a larger culture of HEK293 cells [27]. The virus was 
purified using Adenopure Kit (Puresyn, Malvern, PA). Virus titer was established by 
determining the tissue culture infectious dose 50 (TCID50). Briefly, 10-fold serial 
dilutions of virus in MEM were added to HEK 293 cells in a 96-well flat bottom 
microtiter plate, ten replicates per dilution. Tissue culture plates were incubated at 37oC 
for 10 days, and monitored for cytopathic effect (CPE) in order to calculate the TCID50.  
 4.3.6. Western blotting 
IBRS2 cells or BHK cells were seeded in a 6-well plate at 1x106 cells/well in 3 ml 
supplemented MEM with 10% fetal bovine serum (Hyclone, Logan, UT), 1% non-
essential amino acids (Life Technologies, Grand Island, NY) and 1% Penicillin-
Streptomycin (Life Technologies, Grand Island, NY) incubated for 24 h at 37oC. 
Following attachment, IRBS2 cells were infected with adenovirus Ad5-P1-Ii or Ad5-Blue 
(negative control), BHK cells were infected with FMDV-A24 (positive control) at a 
multiplicity of infection (MOI) of 20 and then incubated for 48 h in a 37oC incubator. 
Whole-cell lysates were harvested and lysed with cell lysis buffer (150mM NaCl, 10mM 
Tris pH 7.6, 1% NP40, 1% DOC) and stored at -80oC until further use. 18 µl of cell 
lysates were mixed with 9 µl of loading dye and were run under denaturing conditions on 
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12% Bis-Tris SDS-PAGE gels (Life Technologies, Grand Island, NY) and transferred 
onto nitrocellulose membranes using Novex mini-cell XCell SureLock electrophoresis 
system (Life Technologies, Grand Island, NY). The blots were probed with FMDV-
specific polyclonal antibodies (mAbs) VP0, 1 and 3 cocktail (1:2000) to detect P1. 
Secondary antibodies were goat α-rabbit IgG (1:2000) (KPL, Gaithersburg, Maryland) 
for the VP cocktail. Pre-stained protein ladder was used as the molecular weight marker 
(ThermoFisher Scientific, Suwanee, GA).  
4.3.7. Tetramer construction 
  Peptides and recombinant BoLA-2*00801 and bovine β2-microglobulin were 
produced and complexed into tetramers as described previously [28]. Briefly, 0.25 µM of 
purified BoLA heavy chain (HC) was incubated with the following: β2m [1.5 µM], 
peptide [4 µM], EDTA (1 mM), pepstatin A (1 µM), 1.10 phenantroline (100 µM), TLCK 
(50 µg/mL), TPCK (100 µM), PMSF (100 µM), Lutrol (0.03%), 50 mM of Tris-maleate 
(pH6.6), in a final volume of 500 µL at 18 °C for 48 h. High molecular weight complexes 
were removed by centrifugation with an Amicon® Ultra Centrifugal Filter Units (Life 
Technologies, Grand Island, NY) at 14,000 g for 10 min. The flow-through was 
recovered and the p-MHC class I complexes were tetramerized at room temperature by 
incubating them with a total of 1.5 µg of phycoerythrin (PE)- streptavidin (BD 
Biosciences, San Jose, CA) starting with 0.45 µg and then adding 0.21 µg every ten min 
over a 50 min period at room temperature and then stored at 4°C.  
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4.3.8. Flow cytometry  
1x106 bovine PBMCs were pelleted and resuspended in a blocking solution 
containing mixture of heat inactivated 5% rat serum (Sigma-Aldrich, St. Louis, MO) and 
5% mouse serum (Sigma-Aldrich, St. Louis, MO) in PBS for 20 min at room 
temperature. Cells were then washed in twice in PBS, and resuspended in 10 µl of 
LIVE/DEAD® fixable yellow cell stain (Life Technologies, Grand Island, NY). Cells 
were incubated for 30 min at 4oC, washed twice in cold PBS, resuspended in 10 µl of 
tetramer and incubated at room temperature for 20 minutes. After incubation cells were 
washed twice in cold FACS buffer (PBS + 0.5% BSA), and resuspended in FACS buffer 
containing CD8 monoclonal antibody ILA51 (IgG1) and CD4 antibody mouse α-bovine 
CD4-FITC (AbD Serotec, Raleigh, NC) and then incubated at room temperature for 30 
min. Cells were washed twice in cold FACS buffer and resuspended in secondary 
antibody rat α-mouse IgG1 BV421 (BD Biosciences, San Jose, CA) and incubated at 
room temperature for 30 min. Cells were washed twice as above, and fixed using 
Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA). Cells were read on the Attune® 
NxT Acoustic Focusing Cytometer (Life Technologies, Grand Island, NY). All cells were 
gated on Live cells/CD8+/Tetramer +, 100,000 events were recorded.  
4.3.9. Serum neutralization assay  
The measurement of endpoint serum neutralization titers of FMDV A24 were 
done as recently described [15, 29]. Briefly, 4-fold heat inactivated serum dilutions were 
incubated at 37oC with either FMDV serotype A24 or Ad5-P1-Ii suspension in cell 
growth medium (50 µl) was added to each well at 100 TCID50 of FMDV serotype A24 
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for 1 hour in a microtiter plate. Cells (BHK for FMDV or HEK 293 for Ad5) from near 
confluent culture were enumerated and diluted in cell culture medium to 1x105 cells/ml, 
then 100 µl of cell suspension was added to all wells. The plates were incubated at 37°C 
for 3 days (FMDV) or 10 days (Ad5-P1-Ii), wells were scored for cytopathic effects and 
endpoint titers were calculated using the Spearman-Karber method, expressed as log10 of 
the reciprocal of the dilution of serum that protects 50% of the wells. Titers above 1.2 
log10 were considered positive for anti-adenovirus antibodies while titers above 0.9 log10 
were considered positive for anti-FMDV antibodies [20].   
4.3.10. ELIspot  
MultiScreen-IP filter plates MAIPS4510 (EMD Millipore, Billerica, MA) were 
pre-wetted with 150 µl 70% ethanol. The plates were washed five times with sterile 
water, and then coated overnight at 4oC with 5 µg/ml monoclonal α-bovine IFN-γ 
antibody (MT17.1) (Mabtech, Cincinnati, OH). The bovine IFN-γ ELIspot kit was used 
according to manufacturer’s instructions (Mabtech, Cincinnati, OH). Two fold dilutions 
of either 2x105 T cells/well or 1x106 PBMCs/well were plated in duplicate and 1 µM of 
peptide was added. The following FMDV peptides were used: 60TTNTQNNDW68, 
653TVYNGTSKY661, 444AAHCIHAEW452, 207LLVAMVPEW215, 443RAAHCIHAEW452, 
604VVRHEGNLTW613, 182DSYAYMRNGW191, and 284KVYANIAPTY293. Cells plated 
with media alone and irrelevant peptide 84KVYANIAPTY293 was used as negative 
controls, as it was a non-binder in the biochemical affinity and stability assays [30]. Spots 
were counted and analyzed with a Zeiss KSL ELIspot automatic reader using the KSL 
ELIspot v2.5 software.  
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4.3.11. Statistical analyses 
Spots from media only wells were subtracted from all experimental wells. IFN-γ 
ELIspot results are shown as the mean ± SD of normalized spots per 2x105 CD8+ T cells. 
Mean and standard deviation were calculated using Microsoft Excel (Mircosoft). 
ANOVA followed by one-way Dunnett’s test was conducted in SPSS (IBM) to compare 
the mean IFN-γ spots generated by CD8+ T cells in response to cells pulsed with peptide 
(relevant verses irrelevant). IFN-γ responses needed to exceed the threshold set as the 
mean responses of irrelevant peptide plus twice the SD. 
4.4. Results 
4.4.1. Ad5-P1-Ii construct results in reduced capsid processing and production of anti-
FMDV antibodies 
Previous work by Patch et al., demonstrated that vaccination of swine with 
Ad5A24 containing a mutation (C163S) of the 3Cpro had reduced processing of P1 into 
mature capsid proteins [15]. We therefore created a second adenovirus construct with the 
same P1 polyprotein derived from FMDV strain A24, but removed the 3Cpro, which is 
involved in processing the viral protein. This construct was then tethered to the BoLA 
class II invariant chain, which we designated as Ad5-P1-Ii. In order to demonstrate the 
impaired activity of 3Cpro in the new construct, IBRS2 cells and BHK cells were infected 
with Ad5-P1-Ii, Ad5-Blue (empty vector) or FMDV strain A24. Cell lysates were 
analyzed by SDS-PAGE followed by Western blotting (Figure 4-1). We detected the 
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presence of P1 cleavage products, VP0 or VP1/3 in the lysates of cells infected with 
FMDV. Cells infected with Ad5-P1-Ii showed more unprocessed P1 (Figure 4-1). The 
empty vector (Ad5-Blue) was negative for an anti-FMDV antibody response.  
  Sera from steers vaccinated and boosted with Ad5-P1-Ii were tested for 
adenovirus or FMDV neutralizing antibodies as described in materials and methods. All 
three steers (176, 184, 185) vaccinated with Ad5-P1-Ii generated adenovirus neutralizing 
antibodies following initial vaccination, with elevated titers following the boost (Figure 
4-2). In contrast, FMDV neutralizing titers in these three animals could only be detected 
following the boost (Figure 4-3). As expected, the steer (182) vaccinated with PBS did 
not have any detectable adenovirus or FMDV neutralizing antibodies (Figure 4-2 and 4-
3). 
 4.4.2. Induction of a virus specific CD8+ T cell response in FMDV vaccinated steers 
  The animals in this study were previously MHC class I typed by PCR using 
sequence specific primers (PCR-SSP), cloning, Sanger sequencing and Illumina MiSeq 
v2.0 (Table 4-1) [30]. We selected these four steers based on the presence of BoLA-
2*00801. This allele was found in relatively high frequency (40%) of Holstein cattle in 
our herd [30]. In addition we previously performed FMDV peptide-MHC affinity and 
stability assays with this target molecule to identify potential FMDV CD8+ T cell 
epitopes [30].   
 At each time point following the initial vaccination or boost, CD8+ T cells or 
PBMCs were freshly isolated and pulsed with individual FMDV peptides identified from 
the previous affinity and stability assays for between 18-20 hours at 37oC. The following 
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day activation of these cells was measured by IFN-γ ELIspot assay (Figure 4-4 and 
Figure 4-6). Peptide (284KVYANIAPTY293) previously identified as a non-binder in the 
affinity and stability assays was used as a negative control in the ELIspot assay [30]. 
Very few PBMCs produced IFN-γ in response these peptides (data not shown). However, 
two peptides, 653TVYNGTSKY215 and 207LLVAMVPEW215, induced a statistically 
significant (p =0.001 and p =.007, respectively) number of IFN-γ producing CD8+ T 
cells in one vaccinated animal (184) (Figure 4-4 and 4-5). These peptides also stimulated 
a slight IFN-γ response in steer 185, but these results were not statistically significant. No 
statistically significant response was detected in the third vaccinated steer (176) or naïve 
steer (182).  
4.4.3. FMDV peptide-BoLA class I tetramer staining was not detected 
In an attempt to show MHC class I restriction, we developed peptide-BoLA 
tetramers for the BoLA molecule expressed by these animals, BoLA-2*00801. Based on 
previous biochemical affinity and stability assays, we identified 7 potential FMDV 
epitopes from P1 that were used to create peptide-BoLA tetramers [30]. As a negative 
control, an eighth BoLA tetramer containing a non-binding peptide 
(284KVYANIAPTY293) identified previously was used as a negative control. PBMCs 
were stained with a live/dead marker, antibodies specific for CD4 and CD8 T cells and 
with tetramer (data not shown). Cells were gated on live/CD4-/CD8+/tetramer+ cells. For 
all steers vaccinated with Ad5-P1-Ii no tetramer staining was detected from all samples 
taken after the initial vaccination or following boost.  
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4.5. Discussion 
In the present study, we hypothesized vaccination of cattle with a T cell directed 
adenovirus vaccine for FMDV (Ad5-P1-Ii) would elicit a CD8+ T cell response that 
could be measured by tetramer staining and IFN-γ release. This vaccine lacked the 3Cpro, 
which prevents P1 capsid protein from being processed. Similar to a study conducted in 
swine, we hoped this would allow for an increase in presentation of peptides on MHC 
class I molecules to CD8+ T cells [15]. We previously identified 7 FMDV peptides that 
bound BoLA-2*00801 with strong affinity and stability as determined by biochemical 
affinity and stability assays [30]. We aimed to verify these 7 peptides as potential CD8+ 
T cell epitopes induced by vaccination with Ad5-P1-Ii. CD8+ T cells are attractive targets 
for enhancing FMDV immunity because they are stimulated by epitopes that are linear, 
extremely small and have the potential to be highly conserved across the various 
serotypes of FMDV [15]. The presence of the serum-neutralizing titers to the adenovirus 
vector were seen 7-21 days after the initial vaccination and again following boost, which 
indicates the animals successfully responded to the vaccination. In contrast, FMD virus-
neutralizing antibodies in the serum were only detected following the boost.  
CD8+ T cells combat viral infection primarily through two mechanisms: direct 
killing of virus infected cells or release of cytokines such as IFN-γ [31]. One 
experimental assay often used to detect (in vitro) direct killing of virus-infected cells is 
the cytotoxic T cell (CTL) killing assay. However, due to two main constraints, the need 
for genetically matched MHC class I alleles of both effector and target cells, as well as 
the cytopathic nature of FMDV, we employed an ELIspot assay to measure IFN-γ release 
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by CD8+ T cells from vaccinated animals in response to stimulation with FMDV specific 
peptides. We showed that a CD8+ T cell response could be detected 4 days post boost 
(Figure 3a). Prior to the boost, CD8+ T cell responses were not detected in any of the 
animals. (Supplemental Figure 1). The level of response varied between the three 
vaccinated steers, one non-responder (176), one mid-responder (185) and one high-
responder (184). Two of the animals (184 and 185) had a biologically relevant response 
on day 4 post boost. This provides evidence to validate our proof of concept study, since 
these animals had a detectable response to the T cell directed Ad5-P1-Ii vaccine.  
Although the response was not as expected, the findings are similar to previous 
studies, the frequency of CD8+ T cells responding to FMDV post vaccination was very 
low [12, 13, 15]. Our findings are also very similar to the study conducted in swine, 
where the CD8+ T cell response was only detected on day 4 post boost [15]. Similar to 
other picornaviruses the main focus of the immune response has been on the development 
of neutralizing antibodies; however, T cell responses are induced and can confer some 
degree of protection against virus challenge. One example is shown with type B 
coxsackieviruses (CVB) infection. Depletion of CD8+ T cells during CVB infection 
leads to increase in viral titers, suggesting CD8+ T cells may have a role in controlling 
the virus [32]. Another example is that infection with Theiler’s murine 
encephalomyocarditis virus (TMEV) results in strong CD8+ T cell responses for which 
several epitopes have been identified [32]. These studies suggest that although CD8+ T 
cells are not commonly found to be major players in combating picornaviral infection, 
they do play an important role.  
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The vaccine in this proof of concept study did not contain an adjuvant; the 
addition of one could have induced a more pronounced CD8+ T cell response. Two 
examples of adjuvants that can induce a strong cytotoxic CD8+ T cell response and 
increase the primary immune response by activating and recruiting antigen presenting 
cells include saponins such as Quil A and cytokines such as granulocyte macrophage 
colony-stimulating factor (GM-CSF) [33].  
The animals in this study were not challenged with FMDV; therefore the 
immunogeneticity of these peptides in terms of clinical protection from disease is yet to 
be determined. Without challenge, the induction of a sufficient CD8+ T cell response is 
difficult to quantify. We do not know if the FMDV peptide specific responses detected 
would be translated into protection or reduced viral load in the cattle, or the sufficient 
amount of memory needed to create an appropriate systemic immune response. Future 
studies should include a FMDV challenge of the vaccinated animals as well as addition of 
an appropriate adjuvant in order to measure the expansion of CD8+ T cells post 
challenge. In addition staining cells with a cytotoxicity marker such as CD107a or 
measuring proliferation with Ki-67 or CFSE dyes are other viable options to determine if 
the CD8+ T cells were proliferating and differentiating in response to vaccination or 
infection.  
 A reverse immunology approach (analyzing the key antigenic peptides presented 
by BoLA 2*00801 of interest) to determine FMDV peptides used in this study limited the 
peptide pool. Therefore, we propose future studies should synthesize the complete 
overlapping peptide library (15 amino acids in length and overlapping by 10 amino acids) 
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spanning the FMDV serotype A24 structural polyprotein P1 to capture any potential 
epitopes that may have been missed.  
Although the response to the epitopes identified was varied, we explored whether 
they were conserved across the other serotypes of FMDV (Supplemental Table 1). 
207LLVAMVPEW215 was conserved across serotypes A22/IRAQ, Asia-1, Type C, Type 
O1/BFS and Type O1/UK. It was not conserved among the SAT 1, 2 and 3 serotypes. 
653TVYNGTSKY215 was not conserved among the other serotypes, except A22/IRAQ; 
however, it was previously described as having strong affinity to swine leukocyte antigen 
(SLA)-1*0401[34]. It is important to identify identical or similar epitopes across the 
different serotypes of FMDV in terms of vaccine design, as a vaccine containing these 
epitopes has the potential to protect against multiple FMDV serotypes.  
MHC class I restriction of the virus specific CD8+ T cells responding in the IFN-
γ ELIspot assay was not supported by BoLA class I tetramer staining of PBMCs derived 
from these animals, as no tetramer specific staining was observed. Two explanations for 
the lack of tetramer positive cells are discussed here. First, the sensitivity of the tetramer 
assay was too low to detect the number of positive T cells. ELIspot assays are more 
sensitive, as they have a lower detection limit of 0.0001%, which exceeds the detection 
limit of intracellular cytokine staining and tetramers [35]. Second, there was no true 
tetramer positive control (i.e., cells expressing the specific T cell receptor of interest). 
One method to generate a tetramer positive control is the mixed lymphocyte peptide 
culture method (MLPC), which uses peptide stimulation and cytokine culture to induce a 
specific T cell response [36]. Another method is development of a transgenic mouse 
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expressing BoLA genes and T cell receptor of interest [37]. These BoLA mice can be 
immunized with FMDV antigens to generate an epitope specific T cell response. 
Regarding the current study, logistical restrictions and the complexity of the BoLA 
limited the feasibility of this option. Finally, a third method is to use a tetramer of a 
different specificity that is positive in cattle, however, this is an assay control and not a 
tetramer positive control. For example, BoLA class I tetramers to measure Theileria 
parva specific T cell responses were recently described and could be used for this 
purpose [28]. An alternative method to tetramer staining to demonstrate MHC restriction 
of IFN-γ producing cells is to use MHC matched target cells. For example, Guzman et 
al., transfected P815 cells with single MHC class I alleles and then used these cells as 
target cells in an ex-vivo IFN-γ ELIspot assay [12, 13]. We decided not to purse this 
option and focused our efforts on tetramer staining, as this was a more novel approach.  
Our results demonstrated a CD8+ T cell response specific for FMDV epitopes 
measured by IFN-γ release after vaccination with T cell directed adenovirus vaccine 
(Ad5-P1-Ii). Previous studies have correlated an increase in IFN-γ production with 
reduced pharyngeal FMDV replication [38]. However, the link between the FMDV 
CD8+ T cell response and protection against disease still remains to be determined. Our 
future studies include addition of an adjuvant in the T cell directed adenovirus vaccine 
and further characterization of CD8+ T cells by proliferation and measurement of 
cytotoxicity after FMDV vaccination and infection. Ultimately, the ideal FMDV vaccine 
will induce both a rapid humoral and cellular immune response, achieve cross protection 
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against many serotypes and generate long-lasting protective immunity, thus providing 
insight into ways to ultimately improve vaccine performance.    
4.6. List of abbreviations 
Foot and Mouth Disease (FMD) 
FMD virus (FMDV) 
Bovine major histocompatibility complex (BoLA) 
Major histocompatibility complex (MHC) 
Differentiate infected from vaccinated animals (DIVA) 
Human adenovirus serotype 5 vector (Ad5-FMD) 
3Cprotease (3Cpro) 
Cytotoxic T cell (CTL) 
Invariant chain (Ii) 
Bovine leukocyte antigen (BoLA; cattle MHC) 
University of Vermont Dairy Center of Excellence (UVM-DCE) 
Peripheral blood mononuclear cells (PBMCs) 
Fetal bovine serum (FBS) 
Roswell Park Memorial Institute (RPMI) 
Swine kidney cells (IBRS2) 
Baby hamster kidney (BHK-21) cells 
Basal medium Eagle (BME)  
Cytopathic effect (CPE) 
Human Embryonic Kidney (HEK) 
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Polyclonal antibodies (mAbs) 
Phycoerythrin (PE) 
Polymerase chain reaction-sequence specific primers (PCR-SSP) 
Granulocyte macrophage colony-stimulating factor (GM-CSF) 
Type B coxsackieviruses (CVB) 
Theiler’s murine encephalomyocarditis virus (TMEV) 
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4.11. Figures and Tables 
 
Table 4-1: Allelic profile of steers used in this study 
Table 1 Allelic profile of steers used in this study   
BoLA Allele  Steer 176 Steer 182 Steer 184 Steer 185 
1*00901 I I   I 
1*01901a P/C A P/C P/C 
1*02001a C P P/C P/C 
1*02301a A       
1*03101 I I I I 
2*00801a P/I P/I P/I P/I 
2*01201a     P   
2*01601a I I   I 
2*02601     I C/I 
2*03201N     I I 
3*00201a I I     
3*01701a   I   I 
3*02702 I I C/I C/I 
4*02401a A A I I 
6*01302a   P     
6*01402   I     
6*01501a     P P 
NC1*00201 I I     
NC1*00301 C C C   
NC1*00501 I       
Typing methods are abbreviated: PCR-SSP (P), Cloning & Sanger sequencing (C), 
Illumina MiSeq v 2.0 (I), all three methods (A) 
aBoLA alleles with PCR-SSP primers available   	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Figure 4-1: Impaired capsid processing of Ad5-FMDV-BIC. IBRS2 cells were infected with the 
indicated virus as described in materials and methods. Following infection, cell lysates were made 
and proteins were separated by SDS-PAGE and visualized by Western blotting using a mix of rabbit 
polyclonal antibodies against FMDV capsid proteins. M: Marker, Lane 1: Ad5-A24, Lane 2: Ad5-























Figure 4-2: Adenovirus Serum Neutralizing Titers (SNT) from steers vaccinated with PBS or Ad5-
P1-Ii. Serum samples were collected following initial vaccination (DPV=days post vaccination) and 
following boost (DPB=days post boost). Blue line is naïve steer (182). Red, green and purple lines 
represent SNT titers for 176, 184, and 185 respectively. SNT were determined as described in 






Figure 4-3: FMDV Serum Neutralizing Titers (SNT) from steers vaccinated with PBS or Ad5-P1-Ii. 
Serum samples were collected following initial vaccination (DPV=days post vaccination) and 
following boost (DPB=days post boost). Blue line is naïve steer (182). Red, green and purple lines 
represent SNT titers for 176, 184, and 185 respectively. SNT were determined as described in 
materials and methods. Dotted line indicates time of boost. 
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Figure 4-4: CD8 T cells from Ad5-P1-Ii two vaccinated animals (184 and 185) gave a slight response 
to two epitopes present in FMDV P1. CD8+ T cells from vaccinated cattle (176, 184, and 185) or 
naïve (182) were stimulated with FMDV peptides overnight and then tested by ELIspot assay for 
antigen-specific IFN-γ release. Values are means plus standard deviations (SD) (error bars) of four 
wells normalized to 2x105 CD8 T cells. Values which are statistically significantly different (p<0.05) 
from the irrelevant peptide are indicated by asterisks. P-value = .001 and .007 for 
653TVYNGTSKY215 and 207LLVAMVPEW215 respectively. Dotted line is the threshold. 
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Figure 4-5: Representative images of the ELIspot wells. The wells are from steer 184 who was 
vaccinated with Ad5-P1-Ii. 653TVYNGTSKY215 (left image) shows a positive CD8+ T cell response 
as compared to spots induced by irrelevant peptide (center image) and ConA assay positive control is 
shown (right image).   
 
 
Figure 4-6: CD8 T cells from Ad5-P1-Ii vaccinated animals (176, 184 and 185) and naïve steer (182) 
only responded on day four boost in the IFN-γ ELIspot assay. All time points the assay was 
performed is shown. Values are means plus standard deviations (SD) (error bars) of four wells 
normalized to 2x105 CD8 T cells. Values which are statistically significantly different (P<0.05) from 
the irrelevant peptide are indicated by asterisks. Dotted line is the threshold. 
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Table 4-2: Supplemental Table 1 
Supplemental	  Table	  1:	  FMDV-­‐derived	  peptides	  across	  serotypes	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   LLVAMVPEW	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   LLVAMVPEW	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   ****L***L	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   ****L***M	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   ********L	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   ********L	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   VAMVPELCK	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   VAMVPELCS	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐	  3	   VAMVPELHS	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   TVYNGTSKY	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   *********	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   YNGKTAYGE	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   YTGTTTYTS	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   VYNGECRYS	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   VYNGNCKYG	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   TA*NGDCK*	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   TV*NGECE*	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   YNGNCKYSE	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   TTNTQNNDW	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   *********	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   *N*******	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   *********	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   *********	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   *********	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   N*QNNDWFS	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   N*QNNDWFS	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   N*QNNDWFS	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   AAHCIHAEW	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   *********	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   HCIHSEWDT	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AAT01753.1	   Type	  C	   HCIHAEWDT	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   AHCIHAEWD	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   AHCIHAEWD	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   SHCYHAEWD	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   ****YHS**	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   HCYHSEWDT	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   RAAHCIHAEW	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   AAHCIHAEW	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   HCIHSEWDT	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   HCIHAEWDT	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   AHCIHAEWD	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   AHCIHAEWD	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   SHCYHAEWD	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   AAHCYHSEW	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   HCYHSEWDT	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   VVRHEGNLTW	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   QYSGTINLHF	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   YSGTMNVHFM	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   YAGTINLHFM	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   QYSGTINLHF	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   QYSGTINLHF	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   YSGTLNLHFM	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   SGSLNYHFMY	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   SGSINLHFMY	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   DSYAYMRNGW	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   **********	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   G*********	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   K*********	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   **********	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   **********	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   HSYIRNGWDV	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   YTYMRNGWDV	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   HAYVRNGWDV	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Accession	  #	   FMDV	  Serotype	   Peptide	  Sequence	  	   	  	   	  	   	  	   	  	  
AAT01710.1	   P1-­‐A24	   KVYANIAPTY	   	  	   	  	   	  	   	  	  
AAT01707.1	   	  A22/IRAQ	   *********H	   	  	   	  	   	  	   	  	  
AAT01743.1	   Asia-­‐1	   ***M*A****	   	  	   	  	   	  	   	  	  
AAT01753.1	   Type	  C	   *********N	   	  	   	  	   	  	   	  	  
AAT01758.1	   Type	  O1/BFS	   *********N	   	  	   	  	   	  	   	  	  
AAT01779.1	   Type	  O/UK	   *********N	   	  	   	  	   	  	   	  	  
AIT55230.1	   SAT-­‐1	   VYVNIAPTNV	   	  	   	  	   	  	   	  	  
AAT01792.1	   SAT-­‐2	   VYANIAPTNV	   	  	   	  	   	  	   	  	  
AAT01796.1	   SAT-­‐3	   YANIAPTNVY	   	  	   	  	   	  	   	  	  
aAmino	  acids	  which	  are	  identical	  to	  the	  amino	  acid	  in	  the	  FMDV	  A24	  sequence	  are	  indicated	  	  
by	  an	  asterisk.	  	  
Bolded	  amino	  acids	  indiciate	  similarities	  with	  the	  A24	  peptide	   	  	  
	  
















5. CHAPTER 5: CONCLUSION 
5.1. Summary  
It was hypothesized that increasing our knowledge on the BoLA class I diversity 
in Holstein cattle and together with the translation of current technologies to assess T cell 
responses would lead to a better understanding of the bovine adaptive immune response 
to FMDV. The objectives of this work were to quantify, define and develop methods to 
detect polymorphisms of the BoLA class I genes of Holstein cattle (Chapter 2), to define 
the FMDV capsid protein peptide repertoire bound by BoLA class I molecules (Chapter 
3) and quantify and define the antigen specific response of Holstein cattle to FMDV 
vaccination (Chapter 4).  
Despite the extensive undertaking to establish the assays and experimental 
approaches to study the BoLA class I diversity and assess the bovine adaptive immune 
response to FMDV, much remains to be understood. We have just begun to scratch the 
surface regarding the diversity in the BoLA class I region. As additional herds in the US 
and worldwide are rapidly and accurately BoLA genotyped using molecular methods, 
such as Illumina, novel alleles or variants of existing alleles will be identified and should 
be deposited into curated databases to further our knowledge on the depth of diversity in 
this region. As a result this can be a starting point to study the genetic basis for disease 
resistance. Very few studies in the literature and now the work presented herein, have 
studied the breed-specific host response to FMDV. Generation of in silico epitope 
predictions in combination with synthetic MHC molecules and vaccine constructs 
specifically designed to target the cellular immune response have changed the way we are 
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able to study the adaptive immune response of livestock. As part of this dissertation, new 
BoLA molecules were synthesized and their peptide binding profiles were analyzed. 
Next, I used the NetMHCpan algorithm to predict several peptides that would bind with 
strong affinity and stability to one of the most common alleles found in our herd (BoLA-
2*00801). These peptide predictions, along with BoLA peptide binding matrix 
predictions (PSCPL), followed by in vitro biochemical affinity and stability assays, 
narrowed the list of potential FMDV peptide epitopes. These peptide epitopes were then 
tested in ELIspot and tetramer assays with cells from animals vaccinated with a T cell 
directed adenovirus vaccine (Ad5-P1-Ii). From this work, two novel FMDV T cell 
epitopes were identified and demonstrated a CD8+ T cell response measured by IFN-γ 
release after vaccination with Ad5-P1-Ii. Based on the methods and results described in 
my dissertation, additional future projects ideas could be undertaken, including those 
discussed below.  
5.2. Further lines of inquiry arising from this work 
5.2.1. Determine the role of adenovirus in bovine CD8 T cell responses 
Previous studies in mice and non-human primates have shown that 
intramuscular immunization with replication-defective recombinant human adenovirus 
serotype 5 (rHuAd5) elicits a CD8+ T cell response with a extended contraction phase 
and sustained memory population (Bassett et al. 2011; Steffensen et al. 2013; Steffensen 
et al. 2012; Tatsis et al. 2007; Yang et al. 2007). The following questions arose after our 
vaccine trial experiment: Did the steers generate a specific T cell response to the human 
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adenovirus 5 vector? Are human and bovine adenoviruses cross-reactive? Did pre-
existing vector immunity from the initial vaccination prevent adenovirus from inducing 
strong CD8+ T cell memory and recall responses following the boost? In order to address 
some of these questions, steers should either be boosted a second time or the initial 
experiment should be repeated with a prime/boost regimen with Ad5-P1-Ii (the construct 
used in the current analysis) or Ad5-EGFP (another construct developed in our 
laboratory) to investigate the phenotype and function of bovine CD8+ T cells induced by 
the adenoviral vectors. To characterize the memory phenotype, the CD8+ T cells should 
be stained with memory cell surface markers CD62L, CCR7 and CD127 (Thakur et al. 
2012). Additionally, an IFN-γ ELIspot, similar to the assay outlined in my dissertation, 
should be performed to identify the function of these CD8+ T cells. Following 
vaccination, the frequencies of epitope-specific CD8+ T cells could be determined by 
either intracellular cytokine staining after incubation with adenovirus-specific peptides or 
with tetramers. To date, only eight CD8 T cell epitopes to adenovirus have been 
identified; the NetMHCpan algorithm could be used to discover additional adenovirus 
peptides (Leen et al. 2008). As shown in mice, preexisting immunity to adenoviral 
vectors (Ad5 and A35) does not interfere with eliciting a CD8 memory and recall 
response; it would be noteworthy to observe if the result is similar in bovine (Steffensen 
et al. 2012). 
A total of 51 human adenovirus serotypes and 8 bovine adenovirus serotypes 
have been identified. It is possible the steers used in the Ad5-P1-Ii vaccine study were 
previously exposed to a bovine adenovirus that interfered with their response to human 
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Ad5 vector. However, this seems unlikely because phylogenetic analysis of the hexon 
protein (capsid protein) indicates human and bovine adenoviruses are quite divergent 
(Davison et al. 2003). Therefore, using the human Ad5 vector as a vaccine delivery 
system in cattle should not be a problem. Adenoviral vectored vaccines have been tested 
in dogs, cats, poultry and livestock (Ferreira et al. 2005). Similar to the Ad5-FMD 
vaccine, other Ad-vectored vaccines have been developed for rabies virus, feline 
immunodeficiency virus, avian infectious bronchitis virus, porcine respiratory and 
reproductive syndrome virus and bovine viral diarrhea virus (Ferreira et al. 2005). 
Adenoviral vectors have been known to induce potent cell-mediated and humoral 
immune responses, making them ideal vaccine vectors against intracellular pathogens 
(Tatsis and Ertl 2004). However, more work needs to be conducted to better understand 
the immune response induced by these vectors in economically important species, such as 
cattle.  
5.2.2. Establish a proteomic approach for epitope discovery  
An alternative method for developing new vaccine candidates is to use 
immunoproteomics (the direct identification of BoLA class I presented epitopes) (Hoppes 
et al. 2010). Immunoproteomics starts with monitoring T cell reactivity upon transfection 
of antigen presenting cells with a pathogen gene of interest. After reactive T cells have 
been identified, smaller protein fragments can be de-convoluted and validated with mass 
spectrometry to reveal the epitope or epitopes. Immunoproteomics has been used to study 
several viruses, such as Influenza and Dengue virus, and to uncover MHC class I specific 
T cell epitopes naturally presented by infected cells (Testa et al. 2012a; Testa et al. 
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2012b). In order to apply this approach to cattle vaccinated or infected with FMDV, 
autologous fibroblasts or mouse P815 cells expressing individual BoLA class I genes 
infected with Ad5-P1-Ii or Ad5-Blue (empty vector) could be used. Fibroblasts generated 
from skin biopsies could be used for MHC class I antigen presentation. The protocol for 
the isolation and generation of these cells has been established in our laboratory, as well 
as others (Childerstone et al. 1999; Kandasamy et al. 2011). The peptide-MHC 
complexes presented on the surface of these cells could be isolated with immunoaffinity 
chromatography using a pan-specific MHC class I antibody (W6/32 or IL-A88) coated 
with protein A/G beads. The bound peptide-MHC complexes are eluted from the beads 
by adding acetic acid. The eluent is then heated to dissociate the bound peptides from the 
MHC molecules. The peptides are separated from the antibody by centrifugation, and the 
purified peptide mixture is then fractionated using high-performance liquid 
chromatography (HPLC) (Figure 5-1). Mass spectrometry is then carried out using 
Orbitrap. HPLC purified peptide fractions are then injected individually into the liquid 
chromatography-mass spectrometry (LC-MS/MS) system to identify the peptide 
sequence (Figure 5-1) (Testa et al. 2012a). The spectra data can be searched using 
SEQUEST search engine on Proteome Discoverer 1.4 (Thermo Fisher Scientific, 
Waltham, MA, USA) against a curated Bovine Uniprot database. The result files will be 
further analyzed by Scaffold 4.3 (Proteome Software, Portland, OR, USA) to compare the 
unique peptide counts and to identify gene ontology functions of the identified proteins.   
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Figure 5-1: Peptide discovery workflow. Figure modified from (Tscharke et al. 2015). 
Alternatively, another approach that could be used for epitope discovery is 
SILAC technology (stable isotope labeling by amino acids in cell culture). In this 
approach, cells with a phenotype of interest are cultured in medium supplemented with 
iostopically labeled amino acids. Reference cells grown in normal medium are used as a 
control. After elution, peptides pools from the reference and experimental cells are 
analyzed by LC-MS/MS and their spectra are compared (Hoppes et al. 2010). 
There are several challenges to the proteomics approach for epitope discovery. 
The analytical challenge lies in discriminating between the peptides identified from 
infected cells and non-infected related peptides that are presented on the cell surface. This 
could be overcome by validating the peptides in cellular assays demonstrating no CD8+ 
T cell reactivity to non-infected cells. Another caveat of this proteomics approach is that 
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this method can identify peptide sequences that have a slightly altered sequence, but are 
recognized by the same TCR as the true T cell epitope (ie, mimotopes). Further 
functional analysis, including tetramer and intracellular cytokine staining involving the 
epitope in question would be needed to verify the true T cell epitope identified by mass 
spectrometry. Regardless of these challenges, proteomics provides an alternative method 
to epitope discovery for studies of cytotoxic T cell immunity, ultimately revolutionizing 
vaccine design.   
5.2.3. Describe functional MHC clustering across BoLA and SLA molecules 
As described earlier MHCcluster is a functional tool used to cluster MHC 
molecules based on their predicted peptide binding specificities. After generation of the 
BoLA MHCcluster tree (Chapter 2), one interesting question arose: Are the functional 
specificities of BoLA similar to those of other important agricultural species, such as 
swine? Figure 5-2 shows the functional specificities of swine leukocyte antigen (SLA) 
molecules (red), BoLA molecules that have not been synthesized (blue) and BoLA 
molecules that have been synthesized (green). The tree highlights the functional overlap 




Figure 5-2: MHCcluster tree of BoLA and SLA molecules. 
Additionally, Table 5-1 identifies similarities and differences in the key anchor 
positions of BoLA and SLA molecules that clustered together on the functional tree. For 
example, SLA and BoLA molecules appear to share amino acids Tyrosine, 
Phenylalanine, Tryptophan and Methionine in position nine. Position two is more 
variable, but common amino acids Valine, Threonine and Serine appear in both BoLA 












































































































































































































































































































































































































































































could potentially help to identify epitopes that could be bound to both BoLA and SLA 
molecules. This tree, however, is a prediction of the functional specificities; whether or 
not the common SLA and BoLA alleles can actually recognize identical epitopes in 
context of vaccination or infection has yet to be determined. Additional biochemical 
affinity and stability data in swine and bovine are needed to validate the peptide binding 
motifs of these molecules. This data can then be used to iteratively train the NetMHCpan 
algorithm, strengthening future epitope predictions. If swine and bovine do have 
functional overlap, the concept of “supertypes” could be extended beyond just humans. 
Therefore, the ideal vaccine would be able to elicit an immune response in multiple 
species. This would be especially important for FMDV vaccine design, as FMDV is 
rampant in developing nations where multiple species are affected and resources are 
limited. 
Many unanswered questions still remain. How important is the distribution of 
commonly expressed BoLA and SLA molecules in terms of protection or susceptibility 
from disease? How does the peptide-BoLA or peptide-SLA complex affect TCR 
activation? How does this correspond to the level of immunogenicity of the peptides? Is it 
possible to predict and monitor immune responses in outbred populations? How will 
these peptide epitopes influence vaccine design? The technologies developed in this 
dissertation can be used as the foundation to address some of these unanswered questions. 
Results generated from the proposed studies will provide knowledge on the mechanisms 
behind the immunological functions, which has implications for animal health.   
 155 
Table 5-1: Key amino acids in anchor positions of SLA and BoLA molecules 
 
5.3. Final Thoughts 
My research contributed to the field of veterinary immunology through the 
production of assays for characterizing the bovine immune response to intracellular 
pathogens, such as FMDV. Although many questions remain unanswered, ultimately, my 
research provided valuable tools for assessing the breed-specific host responses to 
pathogens by translating new technologies that have been applied in human vaccinology 
to the design of bovine vaccines. My research efforts were focused on advancing our 
understanding of BoLA class I antigen presentation and quantifying the antigen-specific 
response to FMDV to better understand adaptive immunity in Holstein cattle. I 
accomplished this by using cutting-edge technologies, including bioinformatics, high-
throughput immunologic assays and development of adenoviral-vectored vaccines. The 
immune response is multifarious, and no branch of the immune system can work alone; 
rather, cell-mediated immunity must work in concert with humoral immunity to combat 
Position'2 Position'3 Position'5 Position'7 Position'9
SLA$1*0401 V,T,L,I D,A,E Y,F,W,M
BoLA$2*07001 T,S,V,A A,D Y,F,M,W
BoLA$2*05401 S,$T D,A,F F,L,Y,I,W,V
BoLA$2*06201 S,L,T,V Y,F,W
BoLA$3*03701 T,S,G,N F,A,Y,I,V,M F A F,L,Y,M,W
BoLA$3*06801 S,G,T,A I,A L F,L,W,I,M
BoLA$3*05801 G,S,T,A F,A F,L,Y,W,M
SLA$2*0401 Y,F,W
SLA$2*0402 F,I,Y,A,V Y,W,F,M
BoLA$2*06901 S,T,V,A Y,F Y,F,W,M
BoLA$2*04301 Y,F,W
BoLA$3*05101 G,S,T F,V Y,F,W,M





the dynamic nature of pathogens. Remarkable progress has been made within the field of 
veterinary immunology and although much work remains, ultimately, this progress is 
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